

ICDS 2015

16th International Coeliac Disease Symposium

June 21–24, 2015
Clarion Congress Hotel Prague

Final Programme

Content

Welcome Messages

Dear Colleagues,

I wish to extend a warm welcome to all participants of the 16th International Coeliac Disease Symposium.

Prague is often considered an ideal venue for the organization of any medical congress. Only in the field of digestive diseases we were in the past honoured to host several top meetings including the Falk symposia, EASL 2003, and even UEGW 2004. Several factors have contributed to the success of those meetings including a conveniently structured congress venue, easy transportation throughout the city, and experienced organizing agencies.

An added value making the meetings truly memorable and enjoyable has been the magic atmosphere and unique beauty of Prague with its countless sights and culinary opportunities. In addition, spirit of Mozart and Kafka is still there making Prague one the most remarkable European cultural centres. At last but not at least, the city is the birthplace of Zdeněk Mařatka, certainly one of the founders of modern gastroenterology and digestive endoscopy.

The Scientific Committee worked hard trying to develop a well-balanced programme composed of free papers from every part of the globe together with invited and state-of-the-art presentations meeting the needs and demands of all participants. As always, an important mission of the meeting is to stimulate young researchers in their effort to further extend the frontiers of our knowledge of coeliac disease. Excellence of their research will be underlined by awarding prizes for the best free papers. It is also to acknowledge the participation of patient groups who are the key stakeholders and beneficiaries of our research.

Certainly it is a meeting not to be missed!

Julius Špičák
Chairman of the Local Organising Committee

Dear colleagues,

It is with great pleasure that I welcome you to ICDS 2015, the 16th International Celiac Disease Symposium. It is amazing to see how much we have learned since the first symposium.

Free exchange of idea's, data and (sometime heated) discussions during the international symposia have certainly contributed to this advance in our knowledge. The symposia have always attracted all those who are fascinated by this disease and give their best to improve our understanding of the mechanisms underlying disease development and finding ways to improve diagnostics procedure and nowadays even come up with novel therapeutic options.

I am confident that ICDS 2015 will be another great success and we owe great thanks to the organisers who have done their very best to ensure another great program in a perfect surrounding, the beautiful city of Prague.

I wish you all an enjoyable, productive and memorable meeting.

Frits Koning
President
International Society of the Study of Celiac Disease

Auspices

The 16th International Coeliac Disease Symposium is held under the auspices of

Ing. Andrej BABIŠ
The First Deputy Prime Minister
for the Economics, Minister of Finance

Prof. MUDr. Tomáš Zima, DrSc., MBA
Rector of the Charles University

Committees & Organizers

International Organising Committee
Nadine Cerf Bensussan *(France)*
Alessio Fasano *(USA)*
Stefano Guandalini *(USA)*
Steffen Husby *(Denmark)*
Frits Koning *(The Netherlands)*
Knut E. A. Lundin *(Norway)*
Ludvig Magne Sollid *(Norway)*
Markku Mäki *(Finland)*
Chris Mulder *(The Netherlands)*
Riccardo Troncone *(Italy)*
Elena F. Verdú *(Canada)*

Local Organising Committee
Julius Špičák, Chairman *(Czech Republic)*

Jiří Bronský *(Czech Republic)*
Pavel Drastich *(Czech Republic)*
Přemysl Frič *(Czech Republic)*
Dana Gabrovská *(Czech Republic)*
Iva Hoffmanová *(Czech Republic)*
Jarmila Kabátová *(Slovak Republic)*
Pavel Kohout *(Czech Republic)*
Jiří Nevoral *(Czech Republic)*
Daniel Sánchez *(Czech Republic)*
Helena Tlaskalová-Hogenová *(Czech Republic)*
Ludmila Tučková *(Czech Republic)*

Faculty List

Julio C. Bai *(Argentina)*
Christophe Benoist *(USA)*
Gerd Bouma *(The Netherlands)*
Jan Bureš *(Czech Republic)*
Carlo Catassi *(Italy)*
Christophe Cellier *(France)*
Hertha Deutsch *(Austria)*
Gerard Eberl *(France)*
Peter R. Gibson *(Australia)*
Marios Hadjivassiliou *(U.K.)*
Anneli Ivarsson *(Sweden)*
Bana Jabri *(USA)*
Katri Kaukinen *(Finland)*
Sibylle Koletzko *(Germany)*
Vladimír Kořínek *(Czech Republic)*
Benjamin Lebwohl *(USA)*

Jonas F. Ludvigsson *(Sweden)*
Govind K. Makharia *(India)*
Maria Luisa Mearin *(The Netherlands)*
Joseph A. Murray *(USA)*
Alina Popp *(Romania)*
David Price *(U.K.)*
Bianca Rootsaert *(The Netherlands)*
David Sanders *(U.K.)*
Olof Sandström *(Sweden)*
Detlef Schuppan *(Germany)*
Carol Semrad *(USA)*
Sarah Sleet *(Belgium)*
Zdenka Ulčová-Gallová *(Czech Republic)*
Lori Welstead *(USA)*
Cisca Wijmenga *(The Netherlands)*

Symposium Venue

Clarion Congress Hotel Prague
Address: Freyova 33, 190 00 Prague 9
Tel.: +420 211 131 139
www.clarioncongresshotelprague.com

The 16th International Coeliac Disease Symposium is being held at the Clarion Congress Hotel Prague which is a state-of-the-art congress center providing high quality services for hosting variety of events.

Clarion Congress Hotel Prague is situated in a modern part of Prague – Vysočany, just 15 minutes from the historical centre of Prague. The excellent transport accessibility and perfect service facilities make it popular both with individual visitors and business clients.

Symposium Secretariat

GUARANT International spol. s r.o.
Na Pankráci 17
140 21 Prague 4
Czech Republic
Tel.: +420 284 001 444
Fax: +420 284 001 448
E-mail: icds2015@guarant.cz

Scientific Secretariat

Institute for Clinical and Experimental Medicine
Hepatogastroenterology Department
Vídeňská 1958/9
140 21 Prague 4 – Krč
Czech Republic

UEMS Credits Information

16th International Coeliac Disease Symposium was granted 15 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME). Event code is 12442.

The 16th International Coeliac Disease Symposium is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme

Scientific Program

Scientific Forum	Clinical Forum	Patient's Forum
Meridian Hall	Zenit Hall	Zenit Hall
Monday, June 22, 2015		
08:30–09:00 Introduction		08:30–09:00 Welcome and introduction
09:00–09:30 Keynote lecture		09:00–10:30 Session I
09:30–10:30 Epidemiology		
10:30–11:00 Coffee break		10:30–11:00 Coffee break
11:00–12:30 Diagnosis		11:00–12:30 Session II
12:30–13:30 Lunch / Poster Session I		12:30–13:30 Lunch
13:30–15:00 Epithelial cells and Pathogenesis I		13:30–15:00 Session III
15:00–15:30 Coffee break		15:00–15:30 Coffee break
15:30–16:30 Genes		15:30–17:30 Session IV
16:30–17:30 Extraintestinal associations		
Tuesday, June 23, 2015		
08:00–10:00 Pathogenesis II	08:30–08:50 Introduction; Keynote lecture	ISSCD General Assembly
	08:50–10:00 Fundamental issues	
10:00–10:30 Coffee break	10:00–10:30 Coffee break	
10:30–11:00 Keynote lecture	10:30–12:00 Behind the intestine I	
11:00–12:20 Non-celiac gluten sensitivity		Nadir Hall
12:20–13:30 Lunch / Poster Session II	12:00–13:30 Lunch	12:30–13:15 ISSCD General Assembly
13:30–15:00 Mucosal healing, complications	13:30–15:00 Behind the intestine II	
15:00–15:30 Coffee break	15:00–15:30 Coffee break	
15:30–17:00 Refractory CD, malignancies	15:30–17:00 CD: Management: Current approaches and perspectives	
Wednesday, June 24, 2015		
08:30–10:00 Primary prevention and screening		
10:00–10:30 Coffee break		
10 30–11:00 Keynote lecture		
11:00–12:30 Novel treatments		

Scientific Forum

Monday, June 22, 2015, Meridian Hall

08:30–09:00 **Introduction**
Koning F, Špičák J, AOECS representatives

09:00–09:30 **Keynote lecture**
Antigen-specific T cell receptors and disease susceptibility
Price D (U.K.)

09:30–10:30 **Epidemiology**
Chairs: Ivarsson A, Makharia GK

20 min **What we have learned from the epidemiological studies**
Ivarsson A (Sweden)

20 min **Celiac disease in Asia**
Makharia GK (India)

10 min **Genome, Environment, Microbiome, and Metabolome biomarkers leading to the development of CD**
Huedo-Medina TB, Leonard MM, Fasano F (USA)

10 min **Different habits on gluten consumption in young european children**
Crespo-Escobar P, Calvo-Lerma J, Auricchio R, Castillejo G, Korponay-Szabo I, Gyimesi J, Martinez-Ojinaga E, Vriezinga S, Werkstetter K, Koletzko S, Polanco I, Mearin ML, Troncone R, Ribes-Koninckx C (Spain, Italy, Hungary, The Netherlands, Germany)

10:30–11:00 **Coffee break**

11:00–12:30 **Diagnosis**
Chairs: Troncone R, Špičák J

20 min **Evolving imaging tools and diagnosis of celiac disease**
Špičák J (Czech Republic)

20 min **Biomarkers for celiac disease**
Troncone R (Italy)

10 min **Prospective study on usefulness of duodenal bulb biopsies in coeliac disease diagnosis**
Taavela J, Popp A, Korponay-Szabo IR, Ene A, Vornanen M, Saavalainen P, Lähdeaho ML, Ruuska T, Laurila K, Parvan A, Anca I, Kurppa K, Mäki M (Finland, Romania, Hungary)

10 min **Search for gluten non-dependent prospective biomarkers for in vitro diagnostic use**
Korponay-Szabo IR, Kerekes-Tóth B, Gyimesi J, Barta-Tóth B, Bogáti R, Király R, Caja Galan S, Nadalutti C, Lindfors K, Maki M, Fésüs L (Hungary, Finland)

10 min **Celiac disease is underdiagnosed in sero-negative, gluten reacting, DQ2/8+ patients with Marsh I.**
Røseth A, Halstenesn T (Norway)

10 min **Clinical features and natural history of potential celiac disease in adults**
Volta U, Caio G, De Giorgio R (Italy)

10 min **Presence of gluten peptides in urine reveals diet transgressions: correlation with mucosal damage**
Rodríguez Herrera A, Moreno Amador MDL, Cebolla Ramírez A, Muñoz Suano A, Carrillo Carrión C, Comino Montilla I, Pizarro Moreno A, León F, Sousa Martín C (Spain, USA)

12:30–13:30 **Lunch / Poster Session I**

13:30–15:00 **Epithelial cells and Pathogenesis I**
Chairs: Tlaskalova – Hogenován H, Cerf Bensussan N

20 min **Wnt signaling in adult intestinal stem cells**
Kořínek V (Czech Republic)

20 min **T cells in celiac disease**
Koning F (The Netherlands)

20 min **B cells and celiac disease**
Sollid LM (Norway)

10 min **Identification and characterization of gluten reactive T cells from the immune repertoire**
Yohannes DA, Freitag T, Kauwe A, Kurppa K, Wacklin P, Mäki M, Anderson R, Kaukinen K, Saavalainen P (Finland, Australia)

10 min **COUR-NP-GLI induce immune tolerance to gliadin and reduce gluten-dependent enteropathy in a celiac mouse model**
Freitag TL, Messing M, Miller SD, Shae LD, Anderson LC, Meri S, Getts DR (Finland, USA)

10 min **The specificity of the T cell response to gluten is stable in celiac disease irrespective of age**
Hardy M, Girardin A, Pizzey C, Cameron DJ, Watson K, Picascia S, Auricchio R, Greco L, Gianfrani C, La Gruta NL, Anderson RP, Tye-Din JA (Australia, Italy, USA)

15:00–15:30 **Coffee**

15:30–16:30 **Genes**
Chairs: Wijmenga C, Sollid LM

20 min **Shared genetics in celiac disease and other autoimmunity disorders**
Wijmenga C (The Netherlands)

10 min **Fine-mapping in the MHC accounts for 18% of additional genetic risk for celiac disease**
Zhernakova A, Gutierrez-Achury J, Pulit S, Trynka G, Hunt K, Romanos J, Raychaudhuri S, van Heel D, de Bakker P, Wijmenga C (The Netherlands, U.K., USA)

10 min **Characterizing TCR γδ T cells in tissues and disease**
Mayassi T, Ladell K, Gamboa R, McLaren J, Ciszewski C, Lesko K, Withoff S, Kupfer S, Semrad C, Guandalini S, Wijmenga C, Li Y, Price D, Jabri B (USA, U.K., The Netherlands)

10 min **Search for high risk gene variants by linkage and targeted resequencing in extended CD pedigrees**
Einarsdottir E, Yohannes D, Koskinen L, Mäki M, Kaukinen K, Korponay-Szabo I, Kurppa K, Saavalainen P (Finland, Hungary)

10 min **Gene expression studies in pediatric and adult celiac disease**
Pascual V, Medrano LM, Bodas A, López-Palacios N, Cuevas D, Jiménez N, González-Pérez B, Salazar I, Núñez C (Spain)

16:30–17:30 **Extraintestinal associations**
Chairs: Bai J, Nevoral J

20 min **Extraintestinal manifestations – introduction**
Bai J (Argentina)

20 min **Gluten-free diet and extraintestinal manifestation**
Guandalini S (USA)

10 min **Anemia and iron deficiency in children with potential celiac disease**
Repo M, Lindfors K, Mäki M, Taavela J, Huhtala H, Laurila K, Vornanen M, Saavalainen P, Kaukinen K, Kurppa K (Finland)

10 min **Increased prevalence of gluten-related disorders and early dysplasia in Barrett‘ esophagus**
Pinto-Sanchez MI, Wolfe M, Basra D, Nardelli A, Chauhan U, Khanna R, Verdu EF, Moayyedi P, Armstrong D, Bercik P (Canada)

Tuesday, June 23, 2015, Meridian Hall

08:00–10:00 **Pathogenesis II**
Chairs: Schuppan D, Jabri B

20 min **Towards optimal model of celiac disease pathogenesis**
Jabri B (USA)

20 min **Beyond gluten: Role of ATIs in NCWS**
Schuppan D (Germany)

20 min **IL-15 in the pathogenesis of celiac disease**
Cerf Bensussan N (France)

10 min **Role of Reovirus as an environmental trigger in the initiation of Celiac Disease**
Bouziat R, Hinterleitner R, Discepolo V, Ikizler M, Dermody T, Jabri B (USA)

10 min **Macrophages favor differentiation of regulatory gliadin-specific IL-10 secreting Tr1 cells via IL-27**
van Leeuwen MA, Costes LMM, van Berkel LA, du Pré MF, Kozijn A, Raatgeep HC, Lindenbergh-Kortleve DJ, van Rooijen N, Koning F, Samsom JN (The Netherlands, Norway)

10 min **Small intestinal bacteria are involved in gluten metabolism in vivo**
Caminero Fernandez A, Galipeau HJ, McCarville JL, Herran AR, Casqueiro J, Surette MG, Verdu EF (Canada, Spain)

10 min **Impact of Interleukin 15 (IL-15) on the development of intestinal dysbiosis**
Meisel M, Koval J, O'Brien S, Mayassi T, Kim S, Fehlner-Peach H, Lesko K, Abadie V, Antonopoulos D, Jabri B (USA)

10 min **Mechanisms of Host-Viral Interactions Mediating Loss of Oral Tolerance a prerequisite for CD**
Hinterleitner R, Bouziat R, Stencel J, Brown J, Ng A, Dermody T, Jabri B (USA)

10 min **Intestinal epithelia lose barrier-function but gain migratory/invasive properties with IL-22**
Lebenheim L, Itzlinger A, Siegmund B, Schulzke JD, Schumann M (Germany)

10:00–10:30 **Coffee break**

10:30–11:00 **Keynote lecture**
Autoimmunity: back to basics
Benoist C (USA)

11:00–12:20 **Non-celiac gluten sensitivity**
Chairs: Lundin K, Verdu E

15 min **Achievements and pitfalls of clinical studies**
Lundin K (Norway)

15 min **Response to gluten and patophysiology of IBS**
Verdu E (Canada)

15 min **There is more to wheat than gluten and more to NCGS than IBS**
Gibson P (Australia)

10 min **Response rate of functional patients after a double blind gluten challenge**
Elli L, Branchi F, Ferretti F, Valiante F, Fini L, Forti E, Cannizzaro R, Londoni C, Lauri A, Fornaciari G, Lenoci N, Borgatta B, Buscarini E (Italy)

10 min **Gluten-free diet in patients with irritable bowel syndrome: a double-blind randomized placebo-control study**
Shahbazkhani B, Sadeghi AS, Malekzadeh R, Rostami-Nejad M, Rostami K (Iran, U.K.)

10 min **Experimental autoimmune encephalopathy enhanced by dietary alpha-amylase/trypsin inhibitors (ATIs)**
Zevallos V, Yogev N, Nikolaev A, Waisman A, Schuppan D (Germany, USA)

12:20–13:00 **Lunch / Poster Session II**

13:30–15:00 **Mucosal healing, complications**
Chairs: Mulder CJ, Murray JA

20 min **Mucosal healing and mortality**
Mulder CJ (The Netherlands)

20 min **Modulation of intestinal epithelial repair**
Murray JA (USA)

10 min **Prevalence of Comorbidities in Patients with Cœliac Disease**
Guandalini S, Tundia N, Thakkar R, Arunajadai S, Macaulay D, Essenmacher K, Fuldeore M (USA)

10 min **Primary prevention of type-1 diabetes mellitus by coeliac mass screening in children**
Korponay-Szabo IR, Szabados K, Pusztai J, Rózsáné Rigó É, Gyimesi J, Hyöty H, Maki M (Hungary, Finland)

10 min **Celiac disease autoimmunity in patients undergoing renal biopsies**
Nurmi R, Mäkelä S, Metso M, Wirta O, Pörsti I, Niemelä O, Mustonen J, Kaukinen K (Finland)

10 min **Prevalence and Predictors of Disordered Eating in Coeliac Disease**
Satherley R, Howard R, Higgs S (U.K.)

10 min **Prevalence of functional GI symptoms among patients with celiac disease: a prospective study**
Silvester JA, Graff LA, Walker JR, Duerksen DR (Canada, USA)

15:00–15:30 **Coffee break**

15:30–17:00 **Refractory CD, malignancies**
Chairs: Cellier C, Lebwohl B

20 min **T cell lymphoma: progress in diagnosis and treatment**
Cellier C (France)

20 min **Mechanisms and possible modulation of nonresponsive celiac disease**
Lebwohl B (USA)

10 min **IL-15 and notch drive the differentiation of sCD3- IEL which undergo malignant transformation in CD**
Meresse B, Montcuquet N, Ettersperger J, Guegan N, Andre-Schmutz I, Di Santo J, Cellier C, Malamut G, Beldjord R, Cerf-Bensussan N (France)

10 min **TNF synergizes with IL2 and IL21 to induce proliferation of aberrant IEL from RCDII patients**
Kooy-Winkelaar Y, Bouwer D, Thompson A, Janssen G, de Ru A, Brugman M, van Gils T, Staal F, Bouma G, van Veelen P, Mulder CJ, Koning F, van Bergen J (The Netherlands)

10 min **Autologous mesenchymal stem cell (MSC) infusions in refractory celiac disease (RCD): a case report**
Ciccocioppo R, Gallia A, Avanzini MA, Cangemi GC, Buonacera A, Brusamolino E, Racca F, Picone C, Vanoli A, Alvisi C, Biagi F, Bergamaschi G, Kruzliak P, Maccario R, Corazza GR (Italy, Czech Republic)

10 min **Revisiting diagnostic features of refractory celiac disease of type I**
Malamut G, Meresse B, Rompteaux P, Khater S, Brousse N, Macintyre E, Cerf-Bensussan N, Cellier C (France)

10 min **Autologous Stem Cell Transplantation (ASCT) for refractory coeliac disease II: The Irish Experience**
Kumar S, Maheshwari P, Harkin G, Goulding C, Hayatt A, Byrnes V (Ireland)

Wednesday, June 24, 2015, Meridian Hall

08:30–10:00 **Primary prevention and screening**
Chairs: Mearin ML, Sandstrom O

20 min **Screening for celiac disease: Yes, but…**
Mearin ML (The Netherlands)

20 min **Early infant feeding and prevention**
Sandstrom O (Sweden)

10 min **Risk of celiac disease in the first degree relatives of patients with celiac disease:A meta-analysis**
Singh P, Arora S, Lal S, Strand T, Makharia G (USA, India, Norway)

10 min **Active Screening of Celiac Disease in At-Risk Children is Justified**
Kivelä L, Kaukinen K, Hiltunen P, Ruuska T, Lähdeaho M-L, Mäki M, Kurppa K (Finland)

10 min **Screening for celiac disease in danish adults**
Horwitz A, Skaaby T, Kårhus LL, Schwarz P, Jørgensen T, Rumessen JJ, Linneberg A (Denmark)

10 min **Elderly subjects screened for celiac disease adapt to and benefit from a gluten free diet**
Cartee AK, Van Dyke C, Brantner T, Larson J, Lahr B, Choung RS, Rubio-Tapia A, Kyle R, Murray JA (USA)

10 min **Primary care testing for coeliac serology is no better than population screening**
Chandler K, Robins G (U.K.)

10:00–10:30 **Coffee break**

10 30–11:00 **Keynote lecture**
Innate lymphoid cells in inflammation and immunity
Eberl G (France)

11:00–12:30 **Novel treatments**
Chairs: Maki M, Fasano A

20 min **Potential targets to speed-up mucosal repair**
Maki M (Finland)

20 min **Intestinal permeability and its regulation by zonulin: diagnostic and therapeutic implications**
Fasano A (USA)

10 min **A GFD Is Insufficient to Control Symptoms and Duodenal Injury in Many Patients with Celiac Disease**
Adelman D, Essenmacher K, Garber M, Marcantonio A, Wu TT, Brantner T, Murray J (USA)

10 min **BL-7010, a Novel Potential Treatment of Celiac Disease – a Phase 1/2 Safety Study in Celiac Patients**
Nisemblat Y, Lähdeaho ML, Scheinin M, Kurppa K, Kärjä-Lahdensuu T, Golan R, Vainstein A, Mäki M (Israel, Finland)

10 min **Rationale for AMG 714, an anti-IL-15 mAb, in the treatment of celiac and refractory celiac disease**
Leon F, Lebrec H, Tsuji W (USA)

10 min **Discovery of CALY-002, best-in-class therapeutic antibody neutralizing human Interleukin-15**
Chvatchko Y, Guégan N, Goffin L, Cerf-Bensussan N, Meresse B, Vicari AP (Switzerland, France)

10 min **Engineering of Kuma030: a Potent Gliadin Endoprotease**
Pultz I, Wolf C, Camarca A, Gianfrani C, Tinberg C, Paski S, Siegel J, Baker D (USA, Italy)

Clinical Forum

Tuesday, June 23, 2015, Zenit Hall

08:30–08:50 **Introduction; Keynote lecture**
What celiac patients expect from experts and community
Deutsch H (Austria)

08:50–10:10 **Fundamental issues**
Chairs: Koning F, Guandalini S

20 min **Celiac disease in childhood and adults: 2014**
Koning F (The Netherlands)

20 min **New view on celiac iceberg – the "Prague" definition 2015**
Ludvigsson JF (Sweden)

20 min **Pathogenesis of celiac disease: orchestration of genetic and enviromental factors**
Catassi C (Italy)

20 min **Progress in diagnosis: Pitfalls in the ESPGAN-work-up**
Husby S (Denmark)

10:10–10:30 **Coffee break**

10:30–12:00 **Behind the intestine I**
Chairs: Ulčová-Gallová Z, Kaukinen K

20 min **Skin manifestation of celiac disease: not only dermatitis herpetiformis**
Kaukinen K (Finland)

20 min **Celiac disease and autoimunity associated conditions in reproductive tract and other organs**
Ulčová-Gallová Z (Czech Republic)

20 min **Bone Alterations in Celiac Disease**
Di Stefano M (Italy)

20 min **Psychiatry and neurology**
Hadjivassiliou M (U.K.)

10 min **Do extra intestinal manifestations of celiac disease improve on GFD?**
Sansotta N (USA)

12:00–13:30 **Lunch**

13:30–15:10 **Behind the intestine II**
Chairs: Lundin K, Bureš J

20 min **Celiac disease nd malignancies**
Sanders DS (U.K.)

20 min **Could we prevent celiac disease and associated autoimunity?**
Troncone R (Italy)

20 min **Eosinophil disease of GIT**
Bouma G (The Netherlands)

20 min **Other non-coeliac enteropathies**
Bureš J (Czech Republi)

20 min **Non celiac gluten sensitivity**
Lundin K (Norway)

15:10–15:30 **Coffee break**

15:30–17:10 **CD: Management: Current approaches and perspectives**
Chairs: Gibson PR, Sollid LM

20 min **Early diagnosis and prevention of CD – Is its relevance appraised in practice?**
Frič P (Czech Republic)

20 min **FODMAP: Non-nutritional effects of food**
Gibson PR (Australia)

20 min **Towards optimal gluten-free diet**
Welstead L (USA)

20 min **Progress in non-dietary therapies**
Sollid LM (Norway)

20 min **How to measure the response to gluten in clinical trials**
Schuppan D (Germany)

Patient's Forum

Monday, June 22, 2015, Zenit Hall

08:30–09:00 **Welcome and introduction**
Floriánová K, Lášková T

09:00–10:30 **SESSION I**
Chairs: Sleet S, Kubík M

20 min **Coeliac disease, Codex and legislative aspects in EU**
Deutsch H (Austria)

20 min **Gluten-free food, testing, methods of analysis**
Kubík M (Czech Republic)

20 min **Patient organizations in Europe**
Rootsaert B (The Netherlands)

20 min **Assuring safety in the gluten-free diet to improve patient outcomes'**
Sleet S (Belgium)

10:30–11:00 **Coffee break**

11:00–12:30 **SESSION II**
Chairs: Lundin K, Kohout P

20 min **Coeliac disease in adults – clinical presentation**
Kohout P (Czech Republic)

20 min **Coeliac disease in children – clinical presentation**
Popp A (Romania)

20 min **Coeliac disease autoimunity in relation to clinical symptoms**
Koletzko S (Germany)

20 min **Allergy to gluten and non-coeliac gluten sensitivity**
Lundin K (Norway)

12:30–13:30 **Lunch**

13:30–15:00 **SESSION III**
Chairs: Husby S, Sandström O

18 min **Is the number of coeliac disease patients increasing worldwide?**
Ivarsson A (Sweden)

18 min **Diagnosis of coeliac disease**
Makharia G (India)

18 min **Specific aspects of coeliac disease diagnosis in children – new ESPGHAN criteria**
Husby S (Denmark)

18 min **The role of genetics in the coeliac disease diagnosis**
Wijmenga C (The Netherlands)

18 min **Screening of coeliac disease**
Sandström O (Sweden)

15:00–15:30 **Coffee break**

15:30–17:30 **SESSION IV**
Chairs: Mearin ML, Mulder C

20 min **Therapy of coeliac disease, gluten-free diet, oats**
Semrad C (USA)

20 min **Prevention of coeliac disease, introduction of gluten into the complementary baby food**
Mearin ML (The Netherlands)

20 min **How to treat complicated coeliac disease?**
Mulder C (The Netherlands)

20 min **Coeliac disease and malignancies**
Sanders D (U.K.)

Posters

Poster Session I* (P001–P089)

Date: Monday, June 22
Time: 12:30–13:30
Room: Poster Area I (Aquarius+Taurus)
Topics: Commorbities and extraintestinal manifestations
Diagnosis
Diet
Epidemiology

**Posters will be displayed throughout the whole Symposium. Please read Instructions for Posters on page 51.*

Commorbities and extraintestinal manifestations

P-001
HEPATITIS B VACCINE NON-RESPONSE IN PEDIATRIC CELIAC DISEASE
Jatla M, Angirekula A
Texas A&M/McLane Childrens Baylor Scott & White, Georgetown, USA

P-002
THE PREVALENCE AND EFFECT OF CONCOMITANT TYPE 1 OR TYPE 2 DIABETES IN ADULT CELIAC DISEASE
Kylökäs A, Kaukinen K, Huhtala H, Collin P, Mäki M, Kurppa K
University of Tampere and Tampere University Hospital, Finland

P-003
PREDICTORS OF GROWTH DISTURBANCE IN CHILDREN WITH CELIAC DISEASE
Nurminen S[1], Kivelä L[1], Taavela J[1], Huhtala H[2], Kaukinen K[1], Mäki M[1], Kurppa K[1]
[1]University of Tampere and Tampere University Hospital, Biokatu Finland; [2]School of Health Sciences, University of Tampere, Lääkärinkatu, Tampere, Finland

P-004
THE EFFECT OF GLUTEN FREE DIET ON THE IMPROVEMENT OF CLINICAL PRESENTATION OF PATIENTS WITH NCGS
Rostami-Nejad M[1], Rostami K[2], Haghazali M[1], Ehsani- Ardakani MJ[1], Sadeghi A[1], Shahbazkhani B[3], Asadzadeh H[1], Zali MR[1]
[1]Gastroenterology and Liver diseases Research Institute, Shahid Beheshti University of Medical Sciences, Velenjak, Tehran, Iran; [2]Department of Gastroenterology, Alexandra Hospital, Redditch, Birmingham, U.K.; [3]Gastroenterology unit, Imam Khomeini Hospital, Tehran University of Medical Sciences, Iran

P-005
OSTEOPOROSIS AND BONE ALTERATIONS IN ADULT CELIAC DISEASE
Hoffmanová I[1], Sánchez D[2], Anděl M[1], Tlaskalová-Hogenová H[2]
[1]Third Faculty of Medicine Charles University, Prague, Czech Republic; [2]Laboratory of Cellular and Molecular Immunology, Institute of Microbiology, Academy of Sciences, Prague, Czech Republic

P-006
BURDEN OF ILLNESS IN DERMATITIS HERPETIFORMIS: A PROSPECTIVE STUDY
Pasternack C[1], Kaukinen K[1,2], Kurppa K[3], Mäki M[3], Collin P[4], Reunala T[1,5], Huhtala H[6], Kekkonen L[7], Salmi T[1,5]
[1]School of Medicine, University of Tampere, Finland; [2]Department of Internal Medicine, Tampere University Hospital, Finland; [3]Tampere Center for Child Health Research, University of Tampere and Tampere University Hospital, Finland; [4]Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Finland; [5]Department of Dermatology, Tampere University Hospital, Finland; [6]Tampere School of Health Sciences, University of Tampere, Finland; [7]Finnish Coeliac Society, Tampere, Finland

P-007
SPLEEN VOLUME BY ABDOMINAL COMPUTED TOMOGRAPHY IN (COMPLICATED) COELIAC DISEASE
van Gils T[1], Nijeboer P[1], van Waesberghe JHTM[1], Janssen QP[1], Zegers JA[1], Nurmohamed SA[1], Kraal G[1], Jiskoot SCI[2], Bouma G[1], Mulder CJJ[1]
[1]VU medical center, De boelelaan, Amsterdam, The Netherlands; [2]St Jansdal, Wethouder Jansenlaan, Harderwijk, The Netherlands

P-008
PSYCHOLOGICAL MANIFESTATIONS OF CELIAC DISEASE IN YOUNG CHILDREN IN THE TEDDY STUDY
Smith LB[1], Lynch K[1], Kurppa K[2], Driscoll K[3], Liu E[4], Koletzko S[5], Johnson SB[3], Agardh D[6]
[1]University of South Florida, Tampa, USA; [2]University of Tampere, Finland; [3]Florida State University, Tallahassee, USA; [4]University of Colorado, Denver, USA; [5]Ludwig Maximilian University, Munich, Germany; [6]Lund UniversityMalmo, Sweden

P-009
OPTIMIZING BEHAVIORAL HEALTH AMONG ADOLESCENTS WITH CELIAC DISEASE
Cordova J, Jericho H, Keenan K, Guandalini S
Univerisity of Chicago, USA

P-010
MORPHOMETRIC CHANGES IN GASTRIC BIOPSIES OF CELIAC CHILDREN
Roslavtseva E, Lysikov Y
Scientific Center for Children's Health, Moscow, Russia

P-011
PRIMARY SCLEROSING CHOLANGITIS (PSC) AND CELIAC DISEASE
Emami MH[3,2,1], Jamali N[1]
[1]Iranian Celiac Association, Isfahan, Iran; [2]Isfahan university of medical sciences, Hazarjerib, Isfahan, Iran; [3]Poursina hakim research institution, Isfahan, Iran

Diagnosis

P-012
COMPARISON OF THE RELIABILITY OF CELIAC DISEASE SEROLOGY TO REFLECT INTESTINAL DAMAGE

Matthias T[4], Jeremias P[4], Neidhöfer S[4], Lerner A[1,2,3]
[1]*Carmel Medical Center, Haifa, Israel;* [2]*B. Rappaport School of Medicine, Bat Galim, Haifa, Israel;* [3]*Technion-Israel Institute of Technology, Naveh Shahanan, Haifa, Israel;* [4]*AESKU.KIPP Institute, Wendelsheim, Germany*

P-013
ANTI-NEO-EPITOPE tTg COMPLEXED TO GLIADIN ARE MORE RELIABLE THEN tTg FOR CELIAC DISEASE DIAGNOSIS

Matthias T[4], Jeremias P[4], Neidhöfer S[4], Lerner A[1,2,3]
[1]*Carmel Medical Center, Haifa, Israel;* [2]*B. Rappaport School of Medicine, Bat Galim, Haifa, Israel;* [3]*Technion-Israel Institute of Technology, Naveh Shahanan, Haifa, Israel;* [4]*AESKU.KIPP Institute, Wendelsheim, Germany*

P-014
PROSPECTIVE ASSESSMENT OF DUODENAL BULB BIOPSIES IN CELIAC DISEASE WITH QUANTITATIVE MORPHOMETRY

Taavela J[1], Popp A[1,2], Lähdeaho ML[1], Hiltunen P[1], Ruuska T[1], Arvola T[3], Anca I[2], Mäki M[1], Kurppa K[1]
[1]*Tampere center for child health research, University of Tampere and Tampere University Hospital, Finland;* [2]*Institute for Mother and Child Care, University of Medicine and pharmacy, Bucharest, Romania;* [3]*Hämeenlinna centaral Hospital, Finland*

P-015
TRICHOBEZOAR AS A PRESENTATION OF PEDIATRIC CELIAC DISEASE

Jatla M, Gardiner L
Texas A&M/McLane Childrens Baylor Scott & White, Georgetown, USA

P-016
DIAGNOSTIC UTILITY OF ANTI-GLIADIN AND ANTI-TISSUE TRANSGLUTAMINASE ANTIBODIES IN CELIAC DISEASE

Maxim R, Trifan A, Girlanu I, Plesa A, Stanciu C
Institute of Gastroenterology and Hepatology, Independentei Avenue, Iasi, Romania

P-017
IMMUNE RESPONSES IN COELIAC DISEASE: COMPARISON OF MARSH 1 WITH MARSH 3 LESIONS

Carrasco A[1,3], Fernández-Bañares F[2,3], Rosinach M[2,3], Zabana Y[2,3], Aceituno M[2,3], Gonzalo V[2,3], Temiño R[2,3], Esteve M[2,3]
[1]*Fundació Mútua de Terrassa, Spain;* [2]*Hospital Universitari Mútua de Terrassa, Spain;* [3]*CIBERehd, Terrassa, Spain*

P-018
THE MARSH III COELIAC MUCOSAL LESION DOES NOT NEED SUBDIVIDING

Marsh MN[1], Johnson MW[1], Rostami K[2]
[1]*Luton and Dunstable Hospital, U.K.;* [2]*Alexandra Hospital, Redditch, U.K.*

P-019
DELAYED CELIAC DISEASE DIANOSIS CAUSES INCREASED USE OF HEALTH CARE SERVICES AND MEDICINES

Fuchs V[1], Kurppa K[1], Huhtala H[2], Collin P[1], Mäki M[1], Kekkonen L[3], Kaukinen K[1]
[1]*University of Tampere and Tampere University Hospital, Finland;* [2]*School of Health Sciences, University of Tampere, Finland;* [3]*Finnish Celiac Society, Finland*

P-020
GLUTEN INTAKE ON THE RISK OF CELIAC DISEASE DURING EARLY CHILDHOOD: THE SWEDISH TEDDY BIRTH COHORT

Andrén Aronsson C[1], Lee H[2], Koletzko S[3], Uusitalo U[2], Yang J[2], Virtanen SM[4], Liu E[5], Norris JM[6], Agardh D[1]
[1]*Department of Clinical Sciences, Lund University, Malmö, Sweden;* [2]*Pediatrics Epidemiology Center, University of South Florida, Tampa, USA;* [3]*Dr. von Hauner Children´s Hospital, Ludwig Maximilians University, Munich, Germany;* [4]*National Institute for Health and Welfare, Helsinki, Finland;* [5]*Digestive Health Institute, University of Colorado Denver, Children´s Hospital Colorado, Denver, USA;* [6]*Department of Epidemiology, University of Colorado Denver, Aurora, USA*

P-021
SEROLOGICAL DIAGNOSIS OF PEDIATRIC CELIAC DISEASE: A PILOT STUDY TOWARD CHANGING PRACTICE IN CANADA

Rajani S[1], Huynh HQ[1,2], Shirton L[1,2], Kluthe C[1,2], Prosser C[1], Meddings J[3], Rempel G[1], Persad R[1,2], Turner J[1,2]
[1]*University of Alberta, Edmonton, Canada;* [2]*Stollery Children's Hospital, Edmonton, Canada;* [3]*University of Calgary, Canada*

P-022
PRE-ENDOSCOPY POINT OF CARE TESTING FOR COELIAC DISEASE IN ANAEMIA: A COST SAVING ECONOMIC MODEL

Mooney P[1], Svabe L[2], Andrews K[2], Moorea S[2], Haythem I[3], Hoque S[3], Elias J[4], Bundhoo K[4], Corbett G[4], Lau M[5], Wong L[5], Tsai H[5], Sanders D[1]
[1]*Royal Hallamshire Hospital, Sheffield, U.K.;* [2]*Bradford Royal Infirmary, Bradford, U.K.;* [3]*Whipps Cross University Hospital, London, U.K.;* [4]*Addenbrookes Hospital, Cambridge, U.K.;* [5]*Hull Royal Infirmary, U.K.*

P-023
HIGH DEFINITION ENDOSCOPY BUT NOT I-SCAN SIGNIFICANTLY INCREASES THE DETECTION OF COELIAC DISEASE

Mooney P[1], Patel N[2], Burden M[1], Wong S[1], Teare J[2], Sanders D[1]
[1]*Royal Hallamshire Hospital, Sheffield, U.K.;* [2]*St Mary's Hospital, London, U.K.*

P-024
THE CLINICAL AND PHENOTYPIC ASSESSMENT OF ULTRA-SHORT COELIAC DISEASE

Mooney P[1], Kurien M[1], Wong S[1], Johnston A[1], Rosario E[1], Cross S[1], Murray J[2], Sanders D[1]
[1]*Royal Hallamshire Hospital, Sheffield, U.K.;* [2]*Mayo Clinic, Rochester, USA*

P-025
COMPARISON OF THREE COMMERCIALLY AVAILABLE POINT OF CARE TESTS FOR COELIAC DISEASE
Mooney P, Burden M, Wong S, Johnston A, Kurien M, Hadjivassiliou M, Sanders D
Royal Hallamshire Hospital, Sheffield, U.K.

P-026
MAGNIVIEW ZOOM ENDOSCOPY FOR THE DETECTION OF MARKERS OF COELIAC DISEASE: A FEASIBILITY STUDY
Mooney P, Burden M, Sanders D
Royal Hallamshire Hospital, Sheffield, U.K.

P-027
CELIAC DISEASE IN THE ERA OF THE NEW ESPGHAN GUIDELINES
Carrato V, Benelli E, Not T, Martelossi S, Ventura A, Zanchi C
IRCSS Burlo Garofolo of Trieste, Italy

P-028
ISOLATED ELEVATION OF DGP IGA ANTIBODIES: LACK OF PREDICTIVE VALUE FOR CELIAC DISEASE
Suarez J, Lebwohl B, Lewis S, Green P
Columbia University, New York, USA

P-029
CELIAC DISEASE AND LYMPHOMA HISTORY
Balihar K[1], Kozeluhova J[1], Hejda V[1], Krcma M[1], Lysak D[2], Gorcikova J[3], Hes O[4], Matejovic M[1]
[1]1st Medical Department, Charles University Medical Faculty and Teaching Hospital, Plzeň, Czech Republic; [2]Department of Hematology and Oncology, Charles University Medical Faculty and Teaching Hospital, Plzeň, Czech Republic; [3]Department of Allergology and Immunology, Charles University Medical Faculty and Teaching Hospital, Plzeň, Czech Republic; [4]Department of Pathology, Charles University Medical Faculty and Teaching Hospital, Plzeň, Czech Republic

P-030
GAMMA-DELTA T-LYMPHOCYTES AS DIAGNOSTIC CRITERIUM IN LATENT COELIAC DISEASE
van Gils T, Nijeboer P, Ooijevaar R, Bontkes HJ, Mulder CJ, Bouma G
VU medical center, Amsterdam, The Netherlands

P-031
CHANGES IN NUTRITIONAL STATUS OF CHILDREN WITH CELIAC DISEASE IN RUSSIA
Roslavtseva E, Bushueva T, Borovik T
Scientific Center for Children's Health, Moscow, Russia

P-032
CAPSULE ENDOSCOPY AND DOUBLE-BALLOON ENTEROSCOPY TO EARLY DETECT SMALL BOWEL TUMORS IN CELIACS
Locatelli M, Tomba C, Branchi F, Conte D, Elli L
Fondazione IRCCS Cà Granda, Milan, Italy

P-033
LYMPHOCYTIC ENTERITIS AND SUSPECTED COELIAC DISEASE: DOUBLE-BLIND GLUTEN VS PLACEBO RECHALLENGE
Rosinach M, Fernandez-Bañares F, Carrasco A, Ibarra M, Temiño R, Gonzalo V, Aceituno M, Esteve M
Hospital Universitari Mutua Terrassa. CIBERehd, Spain

P-034
ARE DUODENAL BIOPSIES NECESSARY FOR THE DIAGNOSIS OF CELIAC DISEASE IN DIABETES MELLITUS TYPE 1 PATI
Absah I, Murray J, Rubio Tapia A, Gebrail R
Mayo Clinic, Rochester, USA

P-035
ADHERENCE TO GLUTEN-FREE DIET AND BARRIERS TO ADHERENCE IN PATIENTS WITH CELIAC DISEASE
Rajpoot P, Sharma A, Harikrishnan S, Baruah BJ, Ahuja V, Makharia GK
All India Institute of Medical Sciences, New Delhi, India

P-036
IMMUNOHISTOCHEMICAL STAINING WITH ANTI-tTG 2 AB IS NOT SPECIFIC FOR CELIAC DISEASE
Das P, Rawat R, Verma AK, Singh G, Vallonthaiel AG, Gahlot GPS, Dinda AK, Ahuja V, Agrawal SK, Datta Gupta S, Makharia GK
All India Institute of Medical Sciences, New Delhi, India

P-037
CELIAC-LIKE ENTEROPATHY IN HELICOBACTER PYLORI INFECTED INDIVIDUALS CARRYING DQ2 AND DQ7 MOLECULES
Popp A[1,2,3], Jinga M[1,4], Balaban V[1,4], Taavela J[2], Saavalainen P[5], Laurila K[2], Anca I[1,3], Mäki M[2]
[1]"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania; [2]Tampere Center for Child Health Research, University of Tampere and Tampere University Hospital, Finland; [3]"Alfred Rusescu" Institute for Mother and Child Care, Bucharest, Romania; [4]"Dr. Carol Davila" Central Military Emergency University Hospital, Bucharest, Romania; [5]Research Programs Unit, Immunobiology, and Department of Medical Genetics, Haartman Institute, Helsinki, Finland

P-038
SMALL INTESTINE DIGITAL HISTOMORPHOMETRY FOR CELIAC DISEASE
Popp A[1,2], Taavela J[1], Isola J[3], Mäki M[1]
[1]Tampere Center for Child Health Research, University of Tampere and Tampere University Hospital, Finland; [2]University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania; [3]Institute of Biosciences and Medical Technology, University of Tampere, Finland

P-039
BLOOD INVESTIGATIONS IN THE DIAGNOSIS AND FOLLOW-UP OF COELIAC CHILDREN: ARE THEY NECESSARY?
Wessels MMS, Veen van II, Vriezinga SL, Putter H, Rings EHHM, Mearin ML
Leiden University Medical Center, The Netherlands

P-040
LEPTIN AND IGF-1 IN PEDIATRIC CELIAC DISEASE AND THEIR RELATIONSHIP WITH PARAMETERS AT DIAGNOSIS
Díez V[1], Etayo V[1], Aznal E[1], Álvarez J[1], Palacios M[2], Vitoria JC[3], Sánchez-Valverde F[1]
[1]Complejo Hospitalario de Navarra. Servicio de Pediatría. Sección de Gastroenterología y Nutrición, Pamplona, Spain; [2]Complejo Hospitalario de Navarra. Servicio de Bioquímica, Pamplona, Spain; [3]Hospital de Cruces. Departamento de Pediatría. Sección de Gastroenterología y Nutrición, Barakaldo, Spain

P-041
CLINICAL FEATURES OF PEDIATRIC CELIAC DISEASE: A TERTIARY-CARE FOCUS ON THE CHANGING PARADIGM
Trovato CM, Montuori M, Valitutti F, Amaro F, Iorfida D, Oliva S, Anania C, Barbato M, Cucchiara S
Sapienza University of Rome, Italy

P-042
HIGH PREVALENCE OF EMA-NEGATIVE CELIAC DISEASE IN A TERTIARY CARE HOSPITAL
Dieli-Crimi R[1], López-Palacios N[2], BodasA[3], Núñez C[1]
[1]Servicio de Inmunología Clínica, Instituto de Investigación Sanitaria de Hospital Clínico San Carlos, Madrid, Spain; [2]Servicio de Aparato Digestivo, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain; [3]Servicio de Pediatría, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain

P-043
HOW DO SWEDISH PEDIATRIC CLINICS DIAGNOSE AND FOLLOW-UP CELIAC DISEASE?
Myléus A[1,2], Stenhammar L[3,4], Björck S[5], Browaldh L[6], Daniels IM[7], Gudjónsdóttir A H[8], Högberg L[3,4], Lindberg E[9], Fagerberg U L[10], Malmquist M[8], Sandström O[1], Ivarsson A[1]
[1]Epidemiology and Global Health, Dept. of Public Health and Clinical Medicine, Umeå University, Sweden; [2]Family Medicine, Dept. of Public Health and Clinical Medicine, Umeå University, Sweden; [3]Pediatric Clinic, Norrköping Hospital, Sweden; [4]Dept. of Clinical and Experimental Medicine, Division of Pediatrics, Linköping University, Sweden; [5]Dept. of Pediatrics, Skane University Hospital, Malmö, Sweden; [6]Dept. of Clinical Science and Education, Karolinska Institutet Sodersjukhuset, Stockholm, Sweden; [7]Pediatric clinic, Uppsala University hospital, Sweden; [8]Dept. of Paediatric Gastroenterologi, Queen Silvia Children´s Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden; [9]Dept. of Paediatrics, Örebro University Hospital, Sweden; [10]Dept. of Pediatrics, Centre for Clinical Research, Västmanland Hospital, Västerås/Karolinska Institutet, Stockholm, Sweden

P-044
CVID ENTEROPATHY MIMICKING COELIAC DISEASE: A CASE REPORT
Macinga P, Sticova E, Hucl T, Spicak J
Institute for Clinical and Experimental Medicine, Prague, Czech Republic

P-045
NORMALIZATION OF CELIAC SEROLOGY IN CHILDREN ON GFD WITH INITIAL TTG > 10 X UPPER LIMIT OF NORMAL
Gidrewicz D[1], Trevenen CL[1], Lyon M[2], Butzner JD[1]
[1]University of Calgary, Alberta Children's Hospiyal, Calgary, Canada; [2]University of Saskatchewan, Royal University Hospital, Saskatoon, Canada

P-046
CLINICAL UTILITY OF QUANTITATIVE MULTI-ANTIBODY POLYCHECK PANELS IN THE DIAGNOSIS OF COELIAC DISEASE
Grzywnowicz M[1], Konopka E[2], Oralewska B[2], Cielecka-Kuszyk J[2], Trojanowska I[2], Cukrowska B[2]
[1]Medical University of Lublin, Poland; [2]The Children's Memorial Health Institute, Warsaw, Poland

P-047
THE USEFULNESS OF ANTI TTG IGG IN THE DIAGNOSIS OF CELIAC DISEASE WHEN ANTI TTG IGA IS NEGA
Absah I, Gebrail R, Rubio Tapia A, Snyder M, Murray J
Mayo Clinic, Rochester, USA

P-048
DOES SEROLOGY ALONE HAVE PREDICTIVE VALUE FOR CELIAC DISEASE DIAGNOSIS?
Chugh PV, Gupta K, Erlichman J, Elci O, Verma R
Children's Hospital of Philadelphia, USA

P-049
PROTOTYPE I-FABP2 ASSAY FOR ASSESSING INTESTINAL DAMAGE IN CELIAC DISEASE PATIENTS
Norman GL[1], Shums Z[1], Milo J[1], Yan S[2], Hansen J[3], Sturgeon C[2], Fasano A[2], Leffler DA[3]
[1]Inova Diagnostics, San Diego, USA; [2]Massachusetts General Hospital for Children, Boston, USA; [3]Beth Israel Deaconess Medical Center, Boston, USA

P-050
EARLY DIAGNOSIS OF CELIAC DISEASE IN IgA DEFICIENT CHILDREN: CONTRIBUTION OF A POINT OF CARE TEST
Bienvenu F[1], Anghel SI[2], Besson Duvanel C[2], Guillemaud J[1], Garnier L[1], Renosi F[1,3] Lachaux A[3], Bienvenu J[1]
[1]Lyon-Sud Hospital-Immunology Laboratory, France; [2]Augurix SA, Monthey, Switzerland; [3]Paediatric Hospital-Gastroenterology-Hepatology-Nutrition Department, Bron, France

Diet

P-051
PREDICTION OF ADHERENCE TO A GLUTEN-FREE DIET AMONG ADULTS WITH CELIAC DISEASE
Dowd AJ[1], Jung ME[1], Chen MY[2], Beauchamp MR[2]
[1]University of British Columbia | Okanagan, Kelowna, Canada; [2]University of British Columbia, Vancouver, Canada

P-052
GLUTEN CONTENT OF WHEAT STARCHES
Šuligoj T, Ellis HJ, Ciclitira PJ
King's College London, U.K.

P-053
IS THE PREVENTIVE LABELLING OF GLUTEN CONFUSING?
Gabrovská D[1], Rysová J[2], Dlabalová J[3], Lášková I[3]
[1]Federation of the Food and Drink Industries, Prague, Czech Republic; [2]Food Research Institute Prague, Czech Republic; [3]Czech Coeliac Society, Prague, Czech Republic

P-054
GLUTEN CONTAMINATION IN COMMERCIAL SPICES IN THE UNITED STATES
Kupper C, Boswell S, Quinn C, Abrahamson K
GFCO, Auburn, WA, USA

P-055
COST AND AVAILABILITY OF GLUTEN-FREE FOODS IN THE UK: IN STORE & ONLINE
Mooney P, Burden M, Blanshard R, White W, Cambray-Deakin D, Sanders D
Royal Hallamshire Hospital, Sheffield, U.K.

P-056
INULIN IN GLUTEN-FREE DIET OF DIFFERENT CALCIUM SUPPLY INFLUENCES CAECAL MICROBIOTA
Krupa-Kozak U, Markiewicz L, Drabińska N, Bączek N, Obrębski M
Institute of Animal Reproduction and Food Research, Polish Academy of Sciences, Olsztyn, Poland

P-057
GLUTEN DETECTION IN FOOD USING AN R5 DIP-STICK SYSTEM: COLLABORATIVE STUDY
Lacorn M[1], Scherf K[2], Weiss T[1], Uhlig S[3]
[1]R-Biopharm AG, Darmstadt, Germany; [2]Deutsche Forschungsanstalt für Lebensmittelchemie, Freising, Germany; [3]QuoData GmbH, Dresden, Germany

P-058
A SHORT DIET ADHERENCE SCORE TESTED IN CHILDREN WITH COELIAC DISEASE
Wessels MMS, Lintelo M, Velde vd R, Putter H, Vriezinga SL, Hopman EG, Mearin ML
Leiden University Medical Center, The Netherlands

P-059
GLUTEN-FREE DIET ADHERENCE IN CELIAC VERSUS NON-CELIAC AMERICAN ADULTS
Smith J
California State University Northridge, USA

P-060
ADHERENCE TO MICRONUTRIENT SUPPLEMENTATION IN CHILDREN WITH CELIAC DISEASE
Mager D.R, Hoffmann M.R, Alzaben A.S, Enns S, Turner J.T
University of Alberta, Li Ka Shing Centre for Research Innovation, Edmonton, Canada

P-061
GLUTEN-FREE PRODUCTS VS THEIR GLUTEN-CONTAINING COUNTERPARTS: AN EQUIVALENT NUTRITIONAL COMPOSITION?
Calvo-Lerma J[1,2], Crespo-Escobar P[1,2], Masip-Simo E[2], Hervás D[1], Ribes-Koninckx C[2,1]
[1]Instituto de Investigación Sanitaria La Fe, Valencia, Spain; [2]Hospital Universitari i Politècnic La Fe, Valencia, Spain

P-062
SEVERE ALLERGY TO CEREALS IN COELIAC PATIENT :A CASE REPORT
De Vitis I [2,1], Caruso C[3,1], Casale C[2,1], Ennas S[2,1], Guidi L[2,1], Armuzzi A[2,1], Papa A[2,1], Rapaccini GL [2,1], Romano A[3,1]
[1]Catholic University of Sacred Heart-Columbus Assoc, Rome, Italy; [2]Internal Medicine & Gastroenterology Unit, Rome, Italy; [3]Allergologiy Unit, Rome, Italy

P-063
ASSESSMENT OF BREAST MILK MYCOTOXIN CONTENT IN MOTHERS WITH CELIAC DISEASE: A PRELIMINARY OUTLINE
De Santis B[3], Valitutti F[1], Nigri A[3], Trovato CM[1], Iorfida D[1], Debegnach F[3], Gregori E[3], De Giacomo M[3], De Luca P[1], Montuori M[1], Neuhold S[4], Cucchiara S[1], Brera C[3], Catassi C[2]
[1]Sapienza University of Rome, Italy; [2]Università Politecnica delle Marche, Ancona, Italy; [3]Istituto Superiore Di Sanità, Veterinary Public Health And Food Safety Department, Rome, Italy; [4]Italian Celiac Society, Genova, Italy

P-064
SELECTIVE CAPTURE OF CELIAC IMMUNOACTIVE PEPTIDES FROM HYDROLYZED GLUTEN BY THE G12 ANTIBODY
Cebolla Ramírez A[1], Moreno Amador MDL[2], Muñoz Suano A[1], López Casado MA[3], Torres López MI[4], Sousa Martín C[2]
[1]Biomedal S.L., Sevilla, Spain; [2]Departamento de Microbiología y Parasitología, Facultad de Farmacia, Universidad de Sevilla, Spain; [3]Departamento de Gastroenterología Pediátrica, Hospital Virgen de las Nieves, Granada, Spain; [4]Departamento de Biología Experimental, Facultad de Ciencias Experimentales, Jaén, Spain

P-065
PREVALENCE AND CHARACTERISTICS OF REACTIONS TO GLUTEN 6 MONTHS AFTER INITIATING A GLUTEN FREE DIET
Silvester JA[2,1], Weiten D[4], Green K[3], Walker JR[1], Graff LA[1], Duerksen DR[1]
[1]University of Manitoba, Winnipeg, Canada; [2]Harvard Medical School, Boston, USA; [3]St Boniface Hospital, Winnipeg, Canada; [4]Grace General Hospital, Winnipeg, Canada

P-066
SELECTED BACTERIA AND FUNGAL ENZYMES TO MANUFACTURE OF GLUTEN-FREE BREAD FROM HYDROLIZED WHEAT FLOUR
Novellini R[1], Marzani B[1], Benedusi A[1], Pinto D[1], Di Salvatore N[1], Gobbetti M[2]
[1]Giuliani spa, Milan, Italy; [2]Department of Science, University Aldo Moro, Bari, Italy

Epidemiology

P-067
THE WORLD INCIDENCE OF CELIAC DISEASE HAS INCREASED OVER THE LAST SIX DECADES

Lerner A[1,2,3], Jeremias P[4], Matthias T[4]
[1]Carmel Medical Center, Haifa, Israel; [2]B. Rappaport School of Medicine, Haifa, Israel; [3]Technion-Israel Institute of Technology, Naveh Shahnan, Haifa, Israel; [4]AESKU.KIPP Institute, Wendelsheim, Germany

P-068
THE ANNUAL INCIDENCE/PREVALENCE OF AUTOIMMUNE DISEASES IS INCREASING WORLDWIDE

Lerner A[1,2,3], Jeremias P[4], Matthias T[4]
[1]Carmel Medical Center, Haifa, Israel; [2]B. Rappaport School of Medicine, Haifa, Israel; [3]Technion-Israel institute of Technology, Naveh Shahanan, Haifa, Israel; [4]AESKU.KIPP Institute, Wendelsheim, Germany

P-069
MATERNAL INFECTIONS IN PREGNANCY AND RISK OF CELIAC DISEASE IN OFFSPRING: A NATIONWIDE COHORT STUDY

Mårild K[1,2], Tapia G[1], Stene LC[1], Størdal K[1,3]
[1]Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway; [2]Department of Medical Epidemiology & Biostatistics, Karolinska Institutet, Stockholm, Sweden; [3]Department of Pediatrics, Østfold Hospital Trust, Fredrikstad, Norway

P-070
SYMPTOMS AND MUCOSAL CHANGES STABLE DURING RAPID INCREASE OF PAEDIATRIC COELIAC DISEASE IN NORWAY

Beitnes AR[1,2], Vikskjold FB[3,4], Jóhannesdóttir GB[3,5], Perminow G[3,6], Olbjørn C[6], Andersen SN[1], Bentsen BS[3], Rugtveit J[3], Størdal K[2,7]
[1]Department of Pathology, Akershus University Hospital, Lørenskog, Norway; [2]Department of Paediatrics, Østfold Hospital Trust, Fredrikstad, Norway; [3]Department of Paediatrics, Oslo University Hospital-Ullevål, Oslo, Norway; [4]Department of Paediatrics, Sørlandet Hospital, Arendal, Norway; [5]Department of Paediatrics, Akureyri Hospital, Eyrarlandsvegur, Akureyri, Iceland; [6]Department of Paediatric and Adolescent Medicine, Akershus University Hospital, Lørenskog, Norway; [7]Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway

P-071
DURATION OF BREASTFEEDING AND RISK OF COELIAC DISEASE IN THE MOBA COHORT

Stordal K[1,2], Dydensborg Sander S[3], Mårild K[1], Lund-Blix NA[4], Husby S[3], Stene LC[1]
[1]National Institute of Public Health, Oslo, Norway; [2]Ostfold Hospital Trust, Fredrikstad, Norway; [3]Syddansk Universitet, Odense, Denmark; [4]Oslo University, Norway

P-072
GLUTEN CONSUMPTION AT EARLY AGE IS DIFFERENT AMONG INFANTS FROM DIFFERENT EUROPEAN COUNTRIES

Crespo-Escobar P[1], Calvo-Lerma J[1], Auricchio R[2], Castillejo G[3], Korponay-Szabo I[4], Gyimesi J[4], Martinez-Ojinaga E[5], Vriezinga S[6], Werkstetter K[7], Koletzko S[7], Polanco I[5], Mearin ML[6], Troncone R[2], Ribes-Koninckx C[1]
[1]Hospital Universitari i Politecnic La Fe, Valencia, Spain; [2]Federico II University Hospital, Naples, Spain; [3]Hospital Universitari Sant Joan, Reus, Spain; [4]Heim Pál Children's Hospital, Budapest, Hungary; [5]Hospital La Paz, Madrid, Spain; [6]Leiden University Medical Center, Leiden, The Netherlands; [7]Ludwig Maximilians University, Munich, Germany

P-073
AGE AT DIGNOSIS AND CLINICAL TYPE OF COELIAC DISEASE: A ROLE IN THE INCIDENCE OF COMPLICATIONS?

Biagi F[1], Schiepatti A[1], Balduzzi D[1], Maiorano G[1], Ciacci Z[2], Zingone F[2], Volta U[3], Caio G[3], Carroccio A[4], Ambrosiano G[5], Mansueto P[5], Gobbi G[1], Corazza G[1]
[1]University of Pavia, Policlinico San Matteo, Pavia, Italy; [2]Dept of Medicine and Surgery, University of Salerno, Italy; [3]Department of Medical and Surgical Sciences, St. Orsola-Malpighi University Hospital, Bologna, Italy; [4]UO di Medicina, Ospedali Civili Riuniti di Sciacca, University of Palermo, Italy; [5]Internal Medicine, University of Palermo, Italy

P-074
PREVALENCE OF CELIAC DISEASE IN INDIAN PATIENTS WITH IBS AND UNINVESTIGATED DYSPEPSIA

Sharma H, Verma AK, Das P, Datta Gupta S, Ahuja V, Makharia GK
All India Institute of Medical Sciences, New Delhi, India

P-075
THE EPIDEMIOLOGY OF CELIAC DISEASE IN ATHLETES: PREVALENCE ESTIMATES AND PRACTICE-BASED IMPLICATIONS

Leone JE[1,2]
[1]Bridgewater State University, USA; [2]Northeastern University, Boston, MA, USA

P-076
GASTROENTERITIS ON THE RISK OF CELIAC DISEASE AUTOIMMUNITY IN YOUNG CHILDREN: THE TEDDY STUDY

Kemppainen KM[1], Lynch K[2], Liu E[3], Lönnrot M[4], Simell V[5], Briese T[6], Koletzko S[7], Hagopian W[8], Rewers M[3], She J-X[9], Simell O[5], Toppari J[5,10], Ziegler A-G.[11,12], Akolkar B[13], Krischer JP[2], Lernmark Å[14], Hyöty H[15,16], Triplett EW[1], Agardh D[14], TEDDY Study Group
[1]Department of Microbiology and Cell Science, University of Florida, Gainesville, USA; [2]Health Informatics Institute, University of South Florida, Tampa, USA; [3]Digestive Health Institute, Children's Hospital Colorado and Barbara Davis Center, CU Denver, Aurora, USA; [4]Department of Virology, School of Medicine and Department of Dermatology, University of Tampere, Kalevantie, Finland; [5]Department of Pediatrics, University of Turku, Turku University Hospital, Kiinamyllynkatu, Finland; [6]Center for Infection and Immunity, Mailman School of Public Health, Columbia University, New York, USA; [7]Dr. von Hauner Children's Hospital, Ludwig Maximilian University, Munich, Germany; [8]Pacific Northwest Diabetes Research Institute, Broadway, Seattle, USA; [9]Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Georgia Regents University; USA; [10]Departments of Physiology and Pediatrics, University of Turku; Kiinamyllynkatu; Finland; [11]Institute of Diabetes Research and Forschergruppe Diabetes e.V, Helmholtz Zentrum München, Neuherberg, Germany; [12]Klinikum rechts der Isar, Technische Universität München, Munich, Germany; [13]National Institute of Diabetes & Digestive & Kidney Diseases, Center Drive, Bethesda; USA; [14]Diabetes and Celiac Disease Unit, Department of Clinical Sciences, Lund University, Malmo, Sweden; [15]Dept of Virology, Medical School, and Dept of Clinical Microbiology, University of Tampere, Kalevantie, Finland; [16]Fimlab Laboratories, Pirkanmaa Hospital District, Biokatu, Tampere, Finland

P-077
DIFFERENCES IN THE COELIAC DISEASE INCIDENCE BETWEEN TWO NEIGHBOURING COUNTRIES:THE DIABIMMUNE STUDY
Simre K[1,2], Uibo O[1,3], Peet A[1,3], Tillmann V[1,3], Hämäläinen AM[4], Siljander H[5], Knip M[5], Uibo R[2]
[1]Children's Clinic of Tartu University Hospital, Lunini , Estonia; [2]Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila, Estonia; [3]Department of Pediatrics, University of Tartu, Lunini , Estonia; [4]Jorvi Hospital, Helsinki University Hospital, Turuntie, Finland; [5]Children's Hospital, University of Helsinki and Helsinki University Hospital, Finland

P-078
EPIDEMIOLOY OF PEDIATRIC CELIAC DISEASE DURING 37 YEARS IN NAVARRA (SPAIN)
Etayo V[1], Diez V[1], Aznal E[1], Bandres E[2], Palacios M[3], Martinez D[1], Justo A[1], Sanchez-Valverde F[1]
[1]Pediatric Service. Complejo Hospitalario de Navarra, Pamplona, Spain; [2]Laboratory of Inmunology. Complejo Hospitalario de Navarra, Pamplona, Spain; [3]Biochemistry Service. Complejo Hospitalario de Navarra, Pamplona, Spain

P-079
CELIAC DISEASE HLA AND NON-HLA RISK PREDICTION IN THE NORWEGIAN MOTHER AND CHILD COHORT STUDY
Tapia G[1], Viken MK[2], Lie BA[2], Mårild K[1], Stene LC[1], Størdal K[1]
[1]Norwegian Institute of Public Health, Oslo, Norway; [2]Oslo University Hospital and University of Oslo, Norway

P-080
HIGH COELIAC DISEASE PREVELANCE IN CYSTIC FIBROSIS
Masip E[1], Clavo J[2], Donat E[1], Polo B[1], Crespo P[2], Ribes-Koninckx C[1]
[1]La Fe hospital, Valencia, Spain; [2]Instituto de Investigación Sanitaria La Fe, Valencia, Spain

P-081
COPING WITH CELIAC DISEASE: HOW MUCH IS THE BURDEN FOR CAREGIVERS?
Ferretti F, Branchi F, Locatelli M, Lombardo V, Conte D, Tomba C, Somalvico F, Elli L
Fondazione IRCCS Ca' Granda, Milano, Italy

P-082
PATIENTS WITH TYPE 1 SPRUE HAVE MORE AUTOIMMUNE DISEASE THAN PATIENTS WITH CELIAC DISEASE
Escudié J.B.[1,2], Cellier C.[1], Malamut G.[1], Khater S.[1], Rance B.[1,2], Burgun A.[1,2], Jannot A.S.[1,2]
[1]European Hospital Georges Pompidou, Paris, France; [2]INSERM UMRS 1138, CRC cordeliers, Paris, France

P-083
GLUTEN INTRODUCTION TO INFANT FEEDING AND CELIAC DISEASE RISK: SYSTEMATIC REVIEW AND META-ANALY
Pinto-Sanchez MI[1], Verdu EF[1], Liu E[3], Bercik P[1], Green PH[2], Murray J[4], Guandalini S[5], Moayyedi P[1]
[1]Department of Medicine, Farncombe Family Digestive Research Institute, McMaster University, Hamilton, Canada; [2]Celiac Disease Center at Columbia University, New York City, USA; [3]Celiac Disease Center-Children' Hospital Colorado, Aurora, USA; [4]Department of Gastroenterology and hepatology, Mayo clinic, Rochester, USA; [5]Department of pediatric gastroenterology, hepatology and nutrition, University of Chicago, USA

P-084
ASSOCIATIONS BETWEEN THE USE OF ANTI-SECRETORY DRUGS AND SUBSEQUENT DEVELOPMENT OF CELIAC DISEASE
Maxim R[1], Trifan A[1], Ciortescu I[1], Plesa A[1], Stanciu C[2]
[1]University of Medicine and Pharmacy "Gr. T. Popa", Iasi, Romania; [2]Institute of Gastroenterology and Hepatology, Iasi, Romania

P-085
IS ONE-TIME SCREENING OF CELIAC DISEASE (CD) SUFFICIENT TO IDENTIFY UNDETECTED CD IN ADULTS?
Choung RS, Khaleghi S, Rubio-Tapia A, Marietta EV, Larson JJ, Lahr VD, Rajkumar V, Murray JA
Mayo Clinic, Rochester, MN, USA

P-086
GEOGRAPHIC VARIATIONS IN PREVALENCE OF CELIAC DISEASE IN ADULTS IN INDIA
Ramakrishna B S[1], Makharia G[2], Chetri K[3], Dutta S[4], Ahuja V[2], Amarchand R[2], Anand K[2], Balamurugan R[1], Chowdhury S[1], Daniel D[1], Dutta Gupta S[2], George G[1], Hellen J[1], Kaur G[2], Pugazhendhi S[1]
[1]Christian Medical College, Vellore, India; [2]All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India; [3]International Hospital, Guwahati, Assam, India; [4]Guwahati Medical College, Guwahati, Assam, India

P-087
HIGH PREVALENCE OF COELIAC DISEASE AMONG CHILDREN IN VAS COUNTY, HUNGARY DETECTED WITH RAPID TEST
Dolinšek J[1], Oroszlan G[2], Balogh M[2], Dolinšek J[3], Mičetić-Turk D[4], Krenčnik T[1]
[1]University Medical Centre Maribor, Slovenia; [2]Markusovszky University Teaching Hospital, Szombathely, Hungary; [3]Municipality Of Maribor, Slovenia; [4]Medical Faculty, University Of Maribor, Slovenia

P-088
CHANGES IN DIAGNOSTIC DELAY AND CLINICAL PATTERN OF CHILDHOOD COELIAC DISEASE IN NE SLOVENIA
Dolinšek J[1], Krenčnik T[1], Ferant Ž[1], Pungartnik A[1], Dolinšek J[2], Mičetić-Turk D[3]
[1]University Medical Centre Maribor, Slovenia; [2]Municipality Of Maribor, Slovenia; [3]Medical Faculty, University Of Maribor, Slovenia

P-089
PERSISTENCE OF IRON-DEFICIENCY ANEMIA IN LONG TERM RESPONDERS CELIAC PATIENTS
Khater S, Malamut G, Saadi R, Cellier C
Hopital Européen Georges Pompidou, Paris, France

Poster Session II* (P090–P192)

Date: Tuesday, June 23
Time: 12:20–13:30
Room: Poster Area II (Leo+Virgo)
Topics: Future directions
Genetics
Immunity and tolerance
Molecular pathways
Non coeliac gluten sensitivity
Refractory disease
Screening
Treatment
Various

**Posters will be displayed throughout the whole Symposium. Please read Instructions for Posters on page 51.*

Future directions

P-090
THE IMPACT OF SOCIAL SUPPORT NETWORK PARTICIPATION ON QUALITY OF LIFE SCORES IN CELIAC DISEASE
Lee A[1,2], Green P[2], Wolf R[2], Verdeli L[2], Contento I[2]
[1]Dr Schar USA, Lyndhurst, USA; [2]Columbia University, New York, USA

P-091
INCREASE USAGE OF FOOD INDUSTRY BACTERIAL TRANSGLUTAMINASE EXPLAINS THE SURGE IN CELIAC DISEASE
Lerner A[1,2,3], Matthias T[4]
[1]Carmel Medical Center, Haifa, Israel; [2]B. Rappaport School of Medicine, Haifa, Israel; [3]Technion-Israel Institute of technology, Naveh Shahanan, Haifa, Israel; [4]Aesku.Kipp Institute, Wendelsheim, Germany

P-092
INTESTINAL PERMEABILITY BREAK BY INDUSTRIAL FOOD ADDITIVES EXPLAINS THE RISING OF AUTOIMMUNITY
Lerner A[1,2,3], Matthias T[4]
[1]Carmel Medical Center, Haifa, Israel; [2]B. Rappaport School of Medicine, Haifa, Israel; [3]Technion-Israel Institute of technology, Naveh Shahanan, Haifa, Israel; [4]Aesku.Kipp Institute, Wendelsheim, Germany

P-093
3-DIMENSIONAL STRUCTURES OF HUMAN AND MICROBIAL TRANSGLUTAMINASES COMPLEXED TO GLIADIN ARE SIMILAR
Jeremias P[1], Neidhöfer S[2], Matthias T[1]
[1]Aesku.Kipp Institute, Wendelsheim, Germany; [2]Aesku.Diagnostcs, Wendelsheim, Germany

P-094
EPIDERMAL TRANSGLUTAMINASE ANTIBODIES ARE NOT GLUTEN-DEPENDENT IN COELIAC DISEASE
Salmi TT[1,2], Kurppa K[2,1], Hervonen K[1,2], Mäki M[2,1], Huhtala H[2], Laurila K[2,1], Collin P[1], Reunala T[2,1], Kaukinen K[2,1]
[1]Tampere University Hospital, Finland; [2]University of Tampere, Finland

P-095
SEROLOGICAL MARKERS OF ENTEROCYTE IMPAIRMENT IN PATIENTS WITH CELIAC DISEASE AND DIABETES MELLITUS
Hoffmanová I[1], Sánchez D[2], Hábová V[2], Anděl M[1], Tučková L[2], Tlaskalová-Hogenová H[2]
[1]Third Faculty of Medicine Charles University, Prague, Czech Republic; [2]Laboratory of Cellular and Molecular Immunology, Institute of Microbiology, Academy of Sciences, Prague, Czech Republic

P-096
DEVELOPMENT OF THE COELIAC DISEASE ASSESSMENT QUESTIONNAIRE (CDAQ)
Crocker H, Peters M, Jenkinson C
University of Oxford, Headington, U.K.

P-097
NOVEL APPROACH TO GLUTEN-FREE DIET EDUCATION: COOKING/ NUTRITION CLASSES FOR CHILDREN AND FAMILIES
Weisbrod V, Ryee M-Y, Stern L, Cines B, Snyder J
Children's National Health System, Washington, DC, USA

P-098
SAFETY STUDY OF ORAL IGY ANTIBODY IN CELIAC DISEASE PATIENTS
Sample D, Gujral N, Hoon HH
University of Alberta, Katz Group Centre for Pharm, Edmonton, Canada

P-099
SELF-COMPASSION AND PSYCHOSOCIAL COPING AMONG ADULTS WITH CELIAC DISEASE
Dowd AJ, Jung ME
University of British Columbia | Okanagan, Kelowna, Canada

P-100
INCREASING ACCESS TO PSYCHOLOGY SUPPORT GROUPS FOR CHILDREN AND ADOLESCENTS WITH CELIAC DISEASE
Ryee M, Freedenberg V, Weisbrod V, Stern L, Hardiman L, Cines B, Synder J
Children's National Health System, Washington DC, USA

P-101
INCREASING THE AWARENESS AND TREATMENT OF THE PSYCHOLOGICAL NEEDS OF CHILDREN WITH CELIAC DISEASE
Ryee M, Weisbrod V, Stern L, Hardiman L, Cines B, Synder J
Children's National Health System, Washington DC, USA

Genetics

P-102
HAPLOTYPES ASSOCIATED WITH CELIAC DISEASE IN THE CZECH POPULATION
Blašková M, Koudová M, Bittóová M, Vlčková Z, Indráková V
GHC GENETICS s.r.o., Prague, Czech Republic

P-103
GENETIC VARIATION OF GENES CCL25 AND CCR9 IN COELIAC DISEASE
Airaksinen L[1,2], Saavalainen P[3], Cerqueira JXM[1,2], Kaukinen K[4,5], Mäki M[1,2], Lindfors K[1,2]
[1]Tampere Center for Child Health Research, University of Tampere, Finland; [2]Tampere University Hospital, Finland; [3]Research Programs Unit, Immunobiology, and Haartman Institute, Department of Molecular Genetics, University of Helsinki, Finland; [4]School of Medicine, University of Tampere, Finland; [5]Department of Internal Medicine, Tampere University Hospital, Finland

P-104
SYSTEM GENETICS APPROACH IDENTIFIES NOVEL LNCRNA GENES AND IMPLICATES AUTOPHAGY IN CELIAC DISEASE
Ricano Ponce I[1], Zhernakova DV[1], Deelen P[1], Karjalainen J[1], Di Tommaso J[1], Borek Z[1], Zorro MM[1], Gutierrez-Achury J[1], BIOS consortium .[2], Jonkers IH[1], Withoff S[1], Li Y[1], Franke L[1], Wijmenga C[1], Kumar V[1]
[1]University Medical Center Groningen, University of, The Netherlands; [2]BIOS Consortium, Leiden, The Netherlands

P-105
SETUP AND EVALUATION OF EFFICACY OF SYBR® GREEN REAL-TIME PCR TECHNIQUE TO DETECT THE HLA-DQ2/8
Mashayekhi K[1,2], Rostami-Nejad M[1], Azimzadeh P[1], Amani D[2], Pourhosseingholi MA[1], Nikzamir AR[3], Zali MR[1]
[1]Gastroenterology and Liver Diseases Research Centers, Shahid Beheshti University of Medical Sciences, Velenjak, Tehran, Iran; [2]Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Velenjak, Tehran, Iran; [3]Biochemical department, School of Medicine, Shahid Beheshti University of Medical Sciences, Velenjak, Tehran, Iran

P-106
HLA TESTING FOR DIAGNOSTICS OF COELIAC DISEASE
Vrana M, Melkova M, Vondrackova H
Institute of Hematology and Blood Transfusion, Prague, Czech Republic

P-107
GENETIC RISK FACTORS FOR THROMBOEMBOLIC COMPLICATIONS IN CELIAC DISEASE
Pitkänen K[1], Laine O[2,3], Kurppa K[2,3], Mäki M[2,3], Kaukinen K[2,3], Saavalainen P[4,5], Koskinen L[4,5]
[1]Tays Heart Hospital, Tampere, Finland; [2]School of Medicine, University of Tampere, Finland; [3]Tampere University Hospital, Finland; [4]Research Programs Unit, Immunobiology, University of Helsinki, Finland; [5]Department of Medical Genetics, Haartman Institute, University of Helsinki, Finland

P-108
PERIPHERAL NEUROTENSIN EXPRESSION IN PEDIATRIC CELIAC DISEASE
Montén C[1], Torinsson Naluai Å[2], Agardh D[1]
[1]Lund University, Malmö, Sweden; [2]Gothenburg University, Sweden

P-109
ISOLATION AND CHARACTERIZATION OF DQ2.5-GLIA-AIA-SPECIFIC ANTIBODIES
Høydahl LS[1,2], DuPre F[1,2], Bergseng E[1,2], Gunnarsen KS[1,2], Qiao SW[1,2], Sollid LM[1,2], Sandlie I[1,2,3], Løset GÅ[1,3,4]
[1]Centre for Immune Regulation, University of Oslo and Oslo University Hospital-Rikshospitalet, Norway; [2]Department of Immunology, Oslo University Hospital-Rikshospitalet, Norway; [3]Department of Biosciences, University of Oslo, Norway; [4]Nextera A/S, Oslo, Norway

P-110
EXPRESSION LEVEL OF CD PREDISPOSING DQA1*05 AND DQB1*02 ALLELES IN APC CARRYING DR3-DQ2.5 HAPLOTYPE
Del Pozzo G[1], Pisapia L[1], Picascia S[2], Camarca A[3], Barba P[1], Gianfrani C[2]
[1]Institute of Genetics and Biophysics"Adriano Buzzati Traverso", CNR, Naples, Italy; [2]Institute of Protein Biochemistry, CNR, Naples, Italy; [3]Institute of Food Sciences, Avellino, Italy

P-111
IRON DEFICIENCY IN TREATED CELIAC DISEASE: CONTRIBUTION OF TMPRSS6 RS855791 POLYMORPHISM
Elli L[1], Poggiali E[1,2], Branchi F[1,2], Tomba C[1,2], Andreozzi F[2], Nava I[1], Bardella MT[1], Duca L[1], Conte D[1,2], Cappellini MD[1,2]
[1]Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy; [2]Università degli Studi di Milano, Italy

P-112
CELIAC DISEASE ASSOCIATED GENES ARE INVOLVED IN INTESTINAL BARRIER FUNCTION
Zorro M, Medrano L, Kumar V, Jaroz L, Wijmenga C, Van IJzendoorn SCD, Withoff S
UMCG Groningen University, The Netherlands

P-113
GENETIC AND NON-GENETIC DETERMINANTS OF CO-OCCURRENCE OF TYPE 1 DIABETES AND CELIAC DISEASE IN TEDDY
Hagopian W[1], Liu E[2], Lee HS[3], Rewers M[2], Ziegler AG[4], She JX[5], Lernmark A[6], Simell O[7], Rich SS[8], Krischer J[3], Erlich H[9], Akolkar B[10], Agardh D[6]
[1]Pacific Northwest Diabetes Research Institute, Seattle, USA; [2]Children's Hospital Colorado, Barbara Davis Center, University of Colorado, Aurora, USA; [3]Health Informatics Institute, University of South Florida, Tampa, USA; [4]Institute of Diabetes Research, Helmholtz Zentrum Munchen, Neuherberg, Germany; [5]Center for Biotechnology and Genomic Medicine, Georgia Regents University, Augusta, USA; [6]Department of Clinical Sciences, Lund University, Skane University Hospital, Malmö, Sweden; [7]Department of Pediatrics, Turku University Central Hospital, Kiinamyllynkatu, Turku, Finland; [8]Center for Public Health Genomics, University of Virginia, Charlottesville, USA; [9]Children's Hospital of Oakland Research Institute, Oakland, USA; [10]Diabetes Branch, NIDDK, NIH, Bethesda, USA

P-114
DYNAMIC EXPRESSION PROFILE OF LNCRNA GENES UPON STIMULATION OF HUMAN GLUTEN-SPECIFIC T-CELLS
Borek Z[1], van Bergen J[2], Kooy-Winkelaar I[2], Kumar V[1], Jonkers I[1], Wijmenga C[1], Koning F[2], Li Y[1], Withoff S[1]
[1]UMCG, Antonius Deusinglaan, Groningen, The Netherlands; [2]LUMC, Albinusdreef, Leiden, The Netherlands

Immunity and tolerance

P-115
INDUSTRIAL FOOD ADDITIVE MICROBIAL TRANSGLUTAMINASE IS IMMUNOGENIC IN CHILDREN WITH CELIAC DISEASE
Lerner A[1,2,3], Matthias T[4], Jeremias P[4], Neidhöfer S[4]
[1]Carmel Medical Center, Haifa, Israel; [2]B. Rappaport School of Medicine, Bat Galim, Haifa, Israel; [3]Technion-Israel Institute of Technology, Naveh Shahanan, Haifa, Israel; [4]AESKU.KIPP Institute, Wedelsheim, Germany

P-116
EPITOPES OF HUMAN AND MICROBIAL TRANSGLUTAMINASES ARE SIMILARLY RECOGNIZED BY CELIAC DISEASE SERA
Jeremias P[4], Prager K[5], Neidhöfer S[5], Lerner A[1,2,3], Matthias T[4]
[1]Carmel Medical Center, Haifa, Israel; [2]B. Rappaport School of Medicine, Bat Galim, Haifa, Israel; [3]Technion-Israel Institute of Technology, Naveh Shahanan, Haifa, Israel; [4]1AESKU.KIPP Institute, Wendelsheim, Germany; [5]AESKU.DIAGNOSTCS, Wendelsheim, Germany

P-117
INJECTION OF TG2-AUTOANTIBODIES INDUCE MILD ENTEROPATHY IN MICE BUT NOT CLINICAL SYMPTOMS
Kalliokoski S[1,2], Sulic AM[1,2], Caja S[1,2], Frias R[3], Laurila K[1,2], Mäki M[1,2], Kaukinen K[1,2], Sblattero D[4], Korponay-Szabo IR[1,5,6], Lindfors K[1,2]
[1]University of Tampere, Finland; [2]Tampere University Hospital, Finland; [3]University of Turku, Finland; [4]University of Eastern Piedmont, Novara, Italy; [5]University of Debrecen, Debrecen, Hungary; [6]Heim Pál Children's Hospital, Budapest, Hungary

P-118
CHARACTERIZATION OF T-CELL RECEPTOR REPERTOIRE OF DQ2.5-GLIA-α2 AND DQ2.5-GLIA-ω2 –REACTIVE T CELLS
Dahal-Koirala S[1,2], Risnes LF[1,2], Christophersen A[1,2], Lundin KEA[1,2,3], Sollid LM[1,2], Qiao SW[1,2]
[1]Centre for Immune Regulation, University of Oslo and Oslo University Hospital, Norway; [2]Department of Immunology, Oslo University Hospital- Rikshospitalet, Norway; [3]Department of Transplantation Medicine, Oslo University Hospital – Rikshospitalet, Norway

P-119
COMPREHENSIVE TCR REPERTOIRE ANALYSIS OF CD4+T CELLS IN GUT AND BLOOD AFTER 14-DAY GLUTEN CHALLENGE
Risnes LF[1,2], Dahal-Koirala S[1,2], Sarna VK[1,2], Lundin KEA[1,2,3], Sollid LM[1,2], Qiao SW[1,2]
[1]Centre for Immune Regulation, University of Oslo and Oslo University Hospital, Norway; [2]Department of Immunology, Oslo University Hospital – Rikshospitalet, Norway; [3]Department of Transplantation Medicine, Oslo University Hospital – Rikshospitalet, Norway

Poster Session I (P001–P089), Monday, June 22
Poster Session II (P090–P193), Tuesday, June 23

P-120
EFFECTS OF DIETARY GLUTEN ON MICE WITH ALTERED STRESS-RELATED BEHAVIOR AND IMMUNOSENESCENCE
Olivares M[1], Benítez-Páez A[1], Cenit MC[1], Garrido A[2], Cruces J[2], De la Fuente M[2], Sanz Y[1]
[1]IATA-CSIC, Paterna (Valencia), Spain; [2]Complutense University of Madrid, Spain

P-121
TG2 AND TG3 ANTIBODIES IN COELIAC DISEASE AND DERMATITIS HERPETIFORMIS – AN ORGAN CULTURE STUDY
Hietikko M[1], Rauhavirta T[1], Hervonen K[1,2], Reunala T[1,2], Salmi T[1,2], Ilus T[1,2], Laurila K[1], Collin P[1,2], Mäki M[1], Kaukinen K[1], Lindfors K[1]
[1]University of Tampere, Finland; [2]Tampere University Hospital, Finland

P-122
GLIADIN-SPECIFIC MABS OF GUT PLASMA CELLS RECOGNIZE LONG PEPTIDES WITH REPEATED MOTIFS
Dørum S[1], Steinsbø Ø[1], Bergseng E[1], Arntzen MØ[2], deSouza GA[3], Sollid LM[1]
[1]Centre for Immune Regulation, University of Oslo, Norway; [2]The Biotechnology Centre of Oslo, Norway; [3]Proteomics Core Facility, Oslo University Hospital-Rikshospitalet, Norway

P-123
INTRAEPITHELIAL INNATE LYMPHOID CELL ALTERATIONS IN CELIAC DISEASE: ROLE IN MUCOSAL INFLAMMATION?
Bunin A, Lewis SK, Lebwohl B, Reizis B, Green PH, Bhagat G
Columbia University, New York, USA

P-124
NO GLIADIN IMMUNOREACTIVITY INDUCED BY HYDROLYZED WHEAT FLOUR IN CELIAC DISEASE CHILDREN
Auricchio R[1], Gianfrani C[2], Picasia S[2], Mandile R[1], Parrella C[1], Gobbetti M[3], Greco L[1]
[1]Department of Traslational Medical Science, University Federico Ii, Naples, Italy; [2]Institute of Protein Biochemistry, CNR, Avellino, Italy; [3]Department of Soil, Plant and Food, University Aldo Moro, Bari, Italy

P-125
ABROGATION OF COELIAC IMMUNOGENICITY OF GLUTEN PEPTIDES BY AMINO ACID POINT SUBSTITUTIONS
Japelj N[1], Côrte-Real B[1], Šuligoj T[1], Zhang W[2], Messing J[2], Ciclitira P J[1]
[1]King's College London, St Thomas' Hospital, London, U.K.; [2]Rutgers University, Waksman Institute of Microbiology , Piscataway, New Jersey, USA

P-126
CYTOKINE PRODUCTION IN THE INTESTINAL MUCOSA OF CHILDREN IN A VERY EARLY PHASE OF COELIAC DISEASE
Gianfrani C[1,2], Camarca A[3], Santarlasci V[4], Picascia S[1], Vitale S[1], Auricchio R[2,5], Liotta F[4], Cosmi L[4], Annunziato F[4], Troncone R[2,5]
[1]Institute of Protein Biochemistry-CNR, Naples, Italy; [2]Department of Translational Medicine, Univ. Federico II, Naples, Italy; [3]Institute of Food Sciences-CNR, Avellino, Italy; [4]Denothe, University of Florence, Florence, Italy; [5]PreventCD Study Group (PreventCD EU-FP6-2005-FOOD4B), Leiden, The Netherlands

P-127
COOPERATION BETWEEN GLUTEN-SPECIFIC B CELLS AND GLUTEN-SPECIFIC T CELLS IN CELIAC DISEASE
du Pre MF, Stamnaes J, Steinsbø O, Sollid LM
University of Oslo and Oslo University Hospital, Norway

P-128
ENHANCED B-CELL RECEPTOR RECOGNITION OF THE AUTOANTIGEN TG2 BY CATALYTIC SELF-MULTIMERIZATION
Stamnaes J.[1,2], Iversen R.[1,2], du Pre M.F[1,2], Chen X.[1,2], Sollid L.M[1,2]
[1]University of Oslo, Centre for Immune Regulation, Norway; [2]Oslo University Hospital, Norway

P-129
IgA-CLASS SWITCH RECOMBINATION OCCURS AT MUCOSAL LEVEL AND IS INCREASED IN CELIAC DISEASE
Lammers KM[1], Hritzo M[2], Serena G[1,2], Sapone A[1], Santora D[2], Casolaro V[3], Fasano A[1]
[1]MGH, Boston, USA; [2]University of Maryland School of Medicine, Baltimore, USA; [3]University of Salerno, Baronissi (SA), Italy

P-130
CXCR3 SPLICE VARIANTS IN CELIAC DISEASE
Lammers KM[1], Serena G[1,2], Barbosa L[1], Sapone A[1], Santora D[2], Casolaro V[3], Fasano A[1]
[1]MGH, Boston, USA; [2]University of Maryland School of Medicine, Baltimore, USA; [3]University of Salerno, Baronissi (SA), Italy

P-131
GLIADIN AND fMLP INDUCE POTENT NEUTROPHIL CHEMOTAXIS BY ENGAGING THE FORMYL PEPTIDE RECEPTOR 1
Lammers KM[1], Chieppa M[2], Liu L[3], Casolaro V[4], Parent CA[3], Fasano A[1]
[1]MGH, Boston, USA; [2]National Institute of Gastroenterology „de Bellis", Castellana Grotte (BA), Italy; [3]NCI, NIH, Medical Center Drive, Bethesda, USA; [4]University of Salerno, Baronissi (SA), Italy

P-132
TRANSAMIDATION OF GLIADIN MEDIATES REVERSAL OF THE ANTIGEN-SPECIFIC IMMUNE PHENOTYPE IN DQ8 TG MICE.
Luongo D, Bonavita R, Rotondi Aufiero V, Maurano F, Bergamo P, Mazzarella G, Rossi M
National Research Council of Italy, Avellino, Italy

P-133
TRANSAMIDATED GLIADIN STIMULATES INTESTINAL IL-10 IN VITRO IN UNTREATED CD PATIENTS
Luongo D[1], Rotondi Aufiero V[1], Iaquinto G[2], Mazzarella G[1], Rossi M[1]
[1]National Research Council of Italy, Avellino, Italy; [2]Gastroenterology Department, San G. Moscati Hospital, Avellino, Italy

P-134
TRANSGENIC DQ2 MICE ON A TOTAL KNOCK OUT BACKGROUND HAVE A SUBOPTIMAL HUMORAL IMMUNE RESPONSE
Madsen CB[1], Kroghsbo S[1], Barington T[2], Hansen TP[3], Bøgh KL[1], Sabir HJ[2], Husby S[2], Toft-Hansen H[2]
[1]Technical University of Denmark, Søborg, Denmark; [2]Odense University Hospital, Denmark; [3]Hvidovre Hospital, Denmark

P-135
STUDY OF ANTIGLIADIN ANTIBODIES AND TOTAL IgA IN BREAST MILK FROM COELIAC AND NON-COELIAC MOTHERS
Roca Llorens M[1], Bolonio M[1], Auricchio R[2], Castillejo G[3], Martínez-Ojinaga E[4], Vriezinga S[5], Hervas D[1], Mena MC[6], Polanco I[4], Troncone R[2], Mearin ML[5], Ribes-Koninckx C[1]
[1]Instituto de Investigación Sanitaria La Fe, Valencia, Spain; [2]University Federico II, Naples, Italy; [3]Hospital Universitari San Joan de Reus, Spain; [4]Hospital Universitario La Paz, Madrid, Spain; [5]Leiden Univerity Medical Center, The Netherlands; [6]Centro Nacional Biotecnología CSIC, Madrid, Spain

P-136
CHARACTERIZATION OF THE T CELL RESPONSE AGAINST IMMUNODOMINANT DQ2.5 EPITOPES IN COELIAC DISEASE
Gunnarsen KS[1,3], Høydahl LS[1,3], Neumann RS[2], Nilssen NR[1,3], Qiao SW[1,3], Sollid LM[1,3], Sandlie IS[1,2,3], Løset GÅ[4,2,1]
[1]Centre for Immune Regulation, University of Oslo and Oslo University Hospital-Rikshospitalet, Norway; [2]Department of Biosciences, University of Oslo, Norway; [3]Department of Immunology, Oslo University Hospital-Rikshospitalet, Norway; [4]Nextera A/S, Oslo, Norway

P-137
ARE ANTI-TRANSGLUTAMINASE ANTIBODIES RELATED ALWAYS TO GLUTEN INGESTION?
Garcia-Peris M[2], Donat E[1], Roca M[3], Masip E[1], Polo B[1], Ribes-Koninckx C[1]
[1]La Fe hospital, Valencia, Spain; [2]Servicio de Pediatría, Hospital LLuís Alcanyís, Valencia, Spain; [3]Laboratorio Gastroenterología Pediátrica Hospital La Fe, Valencia, Spain

P-138
DEVELOPMENT OF GLIADIN CONTAINING TOLEROGENIC IMMUNE MODIFYING NANOPARTICLES FOR CELIAC DISEASE
Smarr CB[2], Freitag TL[3], Shae LD[2], Miller SD[2], Getts DR[2,1]
[1]Cour Pharma, Chicago, USA; [2]Northwestern University, Chicago, USA; [3]Haartman Institute, Helsinki, Finland

P-139
HEALTHY HLA-DQ2.5+ INDIVIDUALS DO NOT MOUNT T-CELL RESPONSES TO GLUTEN EPITOPES
Christophersen A[1], Risnes LF[2], Bergseng E[1], Lundin KEA[2], Sollid LM[1], Qiao SW[1]
[1]Centre for Immune Regulation, University of Oslo, Norway; [2]Centre for Immune Regulation and Oslo University Hospital, Norway

P-140
SPECIFIC NON-GLUTEN PROTEINS OF WHEAT ARE NOVEL TARGET ANTIGENS IN CELIAC DISEASE HUMORAL RESPONSE
Huebener S[1,2,3], Tanaka CK[4], Uhde M[1,2], Zone JJ[5], Vensel WH[4], Kasarda DD[4], Beams L[1,2], Briani C[6], Green PHR[1,2], Altenbach SB[4], Alaedini A[1,2,7]
[1]Department of Medicine, Division of Digestive and Liver Diseases, Columbia University, New York, USA; [2]Celiac Disease Center, Columbia University, New York, USA; [3]Department of Medicine, University Medical Center Hamburg-Eppendorf, Germany; [4]Western Regional Research Center, Agricultural Research Service, United States Department of Agric., Albany, USA; [5]Department of Dermatology, University of Utah, Salt Lake City, USA; [6]Department of Neurosciences, University of Padova, Italy; [7]Institute of Human Nutrition, Columbia University, New York, USA

P-141
LYMPHOCYTE POPULATIONS IN BIOPSIES AND GLUTEN-REACTIVE T CELL LINES FROM CELIAC DISEASE PATIENTS
Steenholt JV, Nielsen C, Staal A, Barington T, Husby S, Toft-Hansen H
Odense University Hospital, Denmark

P-142
DIETARY WHEAT ATIs WORSEN INTESTINAL INFLAMMATION IN MICE WITH COLITIS
Pickert G[1], Heck R[1], Tottenham L[1], Weigert A[2], Zevallos V[1], Schuppan D[1,3]
[1]University Medial Center, Mainz, Germany; [2]Institute of Biochemie I, Goethe-University Frankfurt, Germany; [3]Division of Gastroenterology and Celiac Center, Harvard Medical School, Boston, USA

P-143
THE IL15 AND GLUTEN-DEPENDENT ACTIVATION OF TRANSGLUTAMINASE 2
Kim SM[1], DiRaimondo TR[2], Ernest J[1], Zurenski MA[1], Palanski BA[2], Abadie V[3], Khosla C[2], Jabri B[1]
[1]University of Chicago, Chicago, USA; [2]Stanford University, USA; [3]University of Montreal, Canada

P-144
EPITHELIAL STRESS AND ADAPTIVE IMMUNITY SYNERGIZE TO INDUCE TISSUE DAMAGE IN CD
Discepolo V[1,2], Setty M[2], Abadie V[2], Kamhawi S[2], Mayassi T[2], Ciszweski C[2], Maglio M[1], Semrad C[2], Kupfer S[2], Green P[3], Guandalini S[2], Troncone R[1], Murray J[2], Turner J[2], Jabri B[2]
[1]University Federico II, Napoli, Italy; [2]University of Chicago, USA; [3]Columbia University, Medical Center, New York City, USA

Microbiota interactions

P-145
CDGEMM STUDY DESIGN:A MULTI-OMIC APPROACH TO UNCOVER FACTORS CONTRIBUTING TO THE DEVELOPMENT OF CD
Leonard MM[1], Camhi S[1], Huedo-Medina TB[2], Senger S[1], Serena S[1,3], Sturgeon C[1,3], Fasano A[1]
[1]MassGeneral Hospital for Children, Boston, USA; [2]University of Connecticut., Storrs, USA; [3]University of Maryland School of Medicine, Baltimore, USA

P-146
SHORT CHAIN FATTY ACIDS INFLUENCE THE BARRIER DYNAMICS OF CULTURED INTESTINAL CELLS
Hollén E, Sundqvist T, Holmgren Peterson K
Linköping University, Sweden

P-147
CHARACTERIZATION OF THE ENTIRE CELIAC DISEASE INTESTINAL MICROBIOME BY NEXT GENERATION SEQUENCING
D'Argenio V[1,2], Casaburi G[1], Precone V[1,2], Pagliuca C[1,2], Colicchio R[2], Sarnataro D[1,2], Discepolo V[1,3], Kim SM[4], Salvatore P[2], Ciacci C[5], Monteleone G[6], Caporaso JG[7], Jabri B[4], Salvatore F[1,2,8], Sacchetti L[1]
[1]CEINGE s.c.a r.l., Napoli, Italy; [2]Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, Italy; [3]Department of Medical Translational Sciences and European Laboratory for the Investigation of Food , Napoli, Italy; [4]Department of Medicine and the University of Chicago Celiac Disease Center, University of Chicago, USA; [5]Department of Medicine and Surgery, University of Salerno, Italy; [6]Gastroenterology Unit, University of Torvergata., Rome, Italy; [7]Northern Arizona University, Flagstaff, USA; [8]IRCCS-Fondazione SDN, Napoli, Italy

P-148
THE EFFECT OF GLUTEN FREE DIET ON THE HUMAN MICROBIOME
Zhernakova A[1], Bonder MJ[1], Cai X[2], Tigchelaar E[1], Trynka G[1], Cenit MC[1], Hrdlickova B[1], Zhong H[2], Withoff S[1], Gevers D[3], Wang Y[2], Wijmenga C[1]
[1]UMCG, Groningen, The Netherlands; [2]BGI, Shenzhen, China; [3]Broad Institute of MIT and Harvard, Cambridge, USA

Molecular pathways

P-149
GLIADIN INDUCED OXIDATIVE AND DNA DAMAGE IN CACO2 CELL LINE
Monguzzi E[1], Marabini L[2], Roncoroni L[1], Elli L[1]
[1]Fomadazione IRCCS Cà Granda, Milan, Italy; [2]Università degli studi di Milano, Italy

P-150
P31-43 AND VIRAL LIGAND LOXORIBINE EFFECTS ON THE ACTIVATION OF INNATE IMMUNITY IN CELIAC DISEASE
Nanayakkara M, Lania G, Maglio M, Discepolo V, Auricchio S, Troncone R, Barone MV
University of Naples „Federico II", Italy

P-151
TLR4/MyD88/TRIF/MAPK/NF-kB AND AN NLRP3 INFLAMMASOME ARE INVOLVED IN WHEAT PROTEINS SIGNALING
Palová Jelínková L[1], Dáňová K[1], Drašarová H[1], Dvořák M[2], Funda P[1], Fundová P[1], Kotrbová-Kozak A[3], Černá M[3], Kamanová J[1], Martin SF[4], Freudenberg M[5], Tučková L[1]
[1]Institute of Microbiology, Prague, Czech Republic; [2]1st Medical Faculty, Charles University, Prague, Czech Republic; [3]Third Faculty of Medicine, Charles University, Prague, Czech Republic; [4]Allergy Research Group, Department of Dermatology, University Medical Center Freiburg, Germany; [5]Max Planck Institute for Immunobiology and Epigenetics, Freiburg, Germany

P-152
LONGITUDINAL GENE EXPRESSION ANALYSIS OF CANDIDATE GENES IN COELIAC DISEASE
Galatola M[1,2], Panico C[1], Cielo D[1], Baselice S[1], Gianfrani C[1,2], Greco L[1,2], Auricchio R[1,2]
[1]Department of Translational Medical Science, University of Naples „Federico II", Italy; [2]European Laboratory for Food-Induced disease (ELFID), University of Naples „Federico II", Italy

P-153
Nrf2 ACTIVATION PREVENTS PRO-OXIDANT SIGNS IN A MOUSE MODEL OF GLIADIN-INDUCED ENTEROPATHY
Bergamo P, Cocca E, Maurano F, Luongo D, Rossi M
National Research Council of Italy, Avellino, Italy

P-154
miRNA-REGULATED GENE EXPRESSION DIFFERS IN CELIAC DISEASE PATIENTS ACCORDING TO AGE OF PRESENTATION
Buoli Comani G[1], Elli L[3], Panceri R[2], Biondi A[1,2], Dinelli M[5], Mancuso C[1], Muckenthaler MU[4], Meneveri R[1], Bardella MT[3], Barisani D[1]
[1]Dept. of Health Sciences,University of Milan – Bicocca, Monza, Italy; [2]Fondazione MBBM A.O. S.Gerardo, Monza, Italy; [3]Center for the Prevention and Diagnosis of Celiac Disease and UOC Gastroenterologia ed Endoscopia, F, Milano, Italy; [4]Department of Pediatric Oncology, Hematology and Immunology, University Hospital of Heidelberg, Germany; [5]Unità Endoscopia Digestiva, A. O. S.Gerardo, Monza, Italy

P-155
THE POLYCOMB COMPLEX PRC2 REGULATES THE INTESTINAL STEM CELL NICHE AND MATURATION OF THE ENTEROCYTES
Viiri K[1], Oittinen M[1], Nieminen M[1], Popp A[2], Kurppa K[1], Lindfors K[1], Kaikkonen M[3], Mäki M[1]
[1]University Of Tampere, School of Medicine, Finland; [2]University of Medicine and Pharmacy Carol Davila, Bucharest, Romania; [3]University of Eastern Finland, Kuopio, Finland

P-156
T. MONOCOCCUM OMEGA–GLIADIN PROTECTS AGAINST GLIADIN-INDUCED TOXICITY IN DIFFERENTIATED CACO-2 CELL
Iacomino G[1], Gavitone I[1], Di Stasio L[1], Fierro O[1], Venezia A[2], Mamone G[1]
[1]National Research Council, Avellino, Italy; [2]LILT, Napoli, Italy

P-157
EFFECTS OF IN VIVO GLUTEN CHALLENGE ON BLOOD LEUKOCYTE GENE EXPRESSION PROFILE IN DIET TREATED CELD
Yohannes DA[1], Kauwe A[1], Mäki M[2], Anderson R[3], Linnarsson S[4], Kurppa K[2], Kaukinen K[2], Saavalainen P[1]
[1]Helsinki University, Finland; [2]University of Tampere and Tampere University Hospital, Finland; [3]Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia; [4]Karolinska Institute, Stockholm, Sweden

P-158
CYTOKINES AND GLUTEN-RELATED PEPTIDES AFFECT THE EPITHELIUM SIMILARLY TO PT-GLIADIN DIGEST
Escudero-Hernández C[1], Ruipérez V[1], Martínez-Abad B[1], Garrote J.A.[1,2], Arranz E[1]
[1]IBGM – University of Valladolid, Spain; [2]Hospital Universitario Río Hortega, Valladolid, Spain

Non celiac gluten sensitivity

P-159
IS THERE A RELATIONSHIP BETWEEN GLUTEN INGESTION AND POSTURAL TACHYCARDIA SYNDROME?
Penny H, Ferrar M, Atkinson j, Hoggard N, Hadjivassiliou M, West J, Sanders D
Royal Hallamshire Hospital, Sheffield, U.K.

P-160
DYSPEPSIA COULD BE THE MAIN PRESENTATION OF PATIENTS WITH NON-CELIAC GLUTEN SENSITIVITY
Rostami-Nejad M[1], Rostami K[2], Haghazali M[1], Ehsani- Ardakani MJ[1], Shahbazkhani B[3], Derakhshan F[1], Mohammad-Alizadeh AH[1], Zali MR[1]
[1]Gastroenterology and Liver diseases Research Institute, Shahid Beheshti University of Medical Scienc, Velenjak, Tehran, Iran; [2]Department of Gastroenterology, Alexandra Hospital, Redditch, Birmingham, U.K.; [3]Gastroenterology unit, Imam Khomeini Hospital, Tehran University of Medical Sciences, Iran

P-161
A SINGLE-BLINDED STUDY EVALUATING THE EFFECTS OF A GLUTEN-FREE DIET IN IBS-D
Aziz I, North J, Trott N, Briggs R, Sanders D
Royal Hallamshire Hospital, Sheffield, U.K.

P-162
NON-CELIAC WHEAT SENSITIVITY, ANA POSITIVITY AND AUTOIMMUNE DISEASES: WHAT THE POSSIBLE CORRELATION?
Carroccio A[1,3], D'Alcamo A[1], Soresi M[1], Carta M[1], Adragna F[1], Cavataio F[2], Friscia G[3], Seidita A[1], Taormina G[1], Iacono S[2], Mansueto P[1]
[1]University of Palermo, Italy; [2]Di Cristina Hospital, Palermo, Italy; [3]Giovanni Paolo II Hospital of Sciacca, Italy

P-163
QUESTIONNAIRE SURVEY OF CELIAC DISEASE AND NCGS IN OUTPATIENTS COHORTS OF 3 GASTROENTEROLOGY CENTRES
Kocsis D[1], Bajor J[2], Papp M[3], Miheller P[1], Herszényi L[1], Tulassay Zs[1], Juhász M[1]
[1]Semmelweis University, 2nd Dept. of Internal Medicine, Budapest, Hungary; [2]University of Pécs, 1st Dept. of Internal Medicine, Pécs, Hungary; [3]University of Debrecen, 2nd Dept. of Internal Medicine, Hungary

P-164
DEVELOPMENT OF IN VITRO STRATEGIES AS A DIAGNOSTIC TOOL IN GLUTEN-RELATED PATHOLOGIES
Ruipérez V[1], Escudero-Hernández C[1], Fernández-Salazar L[2], Garrote JA[3,1], Arranz E[1]
[1]University of Valladolid, Spain; [2]Hospital Clínico Universitario, Valladolid, Spain; [3]Hospital Universitario Río Hortega, Valladolid, Spain

P-165
GLUTEN CHALLENGE IN SUSPECTED NON-CELIAC GLUTEN SENSITIVITY
Skodje GI[1], Salte T[2], Drivenes T[2], Toleikyte I[1], Lovik AM[1], Lundin KEA[1]
[1]Oslo University Hospital, Norway; [2]University of Oslo, Norway

P-166
GLUTEN-FREE DIET ADHERENCE IN CELIAC DISEASE AND NON-CELIAC GLUTEN SENSITIVITY
Skodje G[1], Lovik AM[1], Brottveit M[2], Bratlie J[1], Lundin KEA[1]
[1]Oslo University Hospital, Norway; [2]Oslo University Hospital Ulleval, Norway

P-167
COMPARISON OF IMMUNE RESPONSE TO S. CEREVISIAE IN CELIAC DISEASE AND NON-CELIAC GLUTEN SENSITIVITY
Uhde M[1,2], Ajamian M[1,2], Indart A[1,2], Caio G[3], De Giorgio R[3], Green PHR[1,2], Alaedini A[1,2,4]
[1]Department of Medicine, Columbia University, New York, USA; [2]Celiac Disease Center, Columbia University, New York, USA; [3]Department of Medical and Surgical Sciences, University of Bologna, St. Orsola-Malpighi Hospital, Italy; [4]Institute of Human Nutrition, Columbia University, New York, USA

P-168
ALPHA-AMYLASE/TRYPSIN INHIBITORS (ATIs) ACCELERATE MURINE SYSTEMIC LUPUS ERYTHEMATOSUS
Zevallos V[1], Weinmann-Menke J[2], Meineck M[2], Schuppan D[1,3]
[1]University of Mainz, Institute of Translational Immunology, Germany; [2]University of Mainz, Department of Nephrology and Rheumatology, Germany; [3]Harvard Medical School, Division of Gastroenterology and Celiac Center, Boston, USA

Refractory disease

P-169
PREDICTING HISTOLOGICAL REMISSION IN PATIENTS WITH CELIAC DISEASE ON A GLUTEN FREE DIET
Mooney P, Kurien M, Wong S, Burden M, Sanders D
Royal Hallamshire Hospital, Sheffield, U.K.

P-170
REFRACTORY COELIAC DISEASE INDUCED BY IPILIMUMAB/NIVOLUMAB COMBINATION THERAPY
Harkin G, Leonard G, Byrnes V
University College Hospital Galway, Ireland

Screening

P-171
IMPROVEMENT OF PROLYLENDOPEPTIDASE ACTIVITY BY SITE-SPECIFIC POLYMER CONJUGATION
Schulz J D, Patt M, Kries H, Hilvert D, Leroux J-C
ETH Zurich, Switzerland

P-172
PRIMARY CARE TESTING FOR COELIAC SEROLOGY IS NO BETTER THAN POPULATION SCREENING
Chandler K, Robins G
The York Hospital, U.K.

P-173
CHILDREN WITH TYPE 1 DIABETES SHOULD BE SYSTEMATICALLY SCREENED FOR CELIAC DISEASE
Laitinen A[1], Kivelä L[1], Huhtala H[2], Lähdeaho ML[1], Mäki M[1], Kaukinen K[1], Kurppa K[1]
[1]University of Tampere and Tampere University Hospital, Finland; [2]School of Health Sciences, Tampere, Finland

P-174
CLINICAL VALUE OF HLA GENOTYPING IN SCREENING FOR CELIAC DISEASE: A FOLLOW-UP BIRTH COHORT STUDY
Björck S, Brundin C, Agardh D
Unit of Diabetes and Celiac Disease, Lund University, Malmö, Sweden

P-175
COST-EFFECTIVENESS OF ROUTINE DUODENAL BIOPSY FOR CELIAC DISEASE TESTING DURING ENDOSCOPY FOR REFLUX
Yang J, Thanataveerat A, Green P, Lebwohl B
Columbia University, New York, USA

P-176
CELIAC DISEASE SYMPTOMS IN ATHLETES: PREVALENCE AND INDICATORS OF PERCEIVED QUALITY OF LIFE
Leone JE[1,3], Jordan CA[1], Wise KA[1], Mullin EM[2]
[1]Bridgewater State University, USA; [2]Springfield College, USA; [3]Northeastern University, Boston, USA

P-177
AUTOIMMUNITY IN A HIGH RISK GROUP: BUILDING A FAMILY-BASED MODEL OF AUTOIMMUNE DISEASE
Leonard MM[1], Huedo-Medina TB[2], Camhi S[1], Sturgeon C[3,1], Fasano A[1]
[1]MassGeneral Hospital for Children, Boston, USA; [2]University of Connecticut, Storrs, USA; [3]University of Maryland School of Medicine, Baltimore, USA

P-178
INHIBITION OF GLIADIN INDUCED IMPAIRED INTESTINAL INTEGRITY AND INFLAMMATION USING EGG YOLK ANTIBODY
Gujral N, Sunwoo HH
University of Alberta, Edmonton, Canada

P-179
ELEVATED BMI AT INITIAL DIAGNOSIS OF CELIAC DISEASE
Bierly P, Verma R
The Childrens's Hospital of Phila, Willow Grove, USA

P-180
IMPLEMENTATIONS OF THE NEW ESPGHAN GUIDELINES OF CD IN THE NETHERLANDS
Landman M[1], Theuns-Valks SDM[2], van Wering HM[3], Tramper-Stranders GA[4], van Ledden M[5], Rietveld E[6], van der Lely N[7], Escher JC[8], Groeneweg M[1]
[1]Maasstad Hospital Rotterdam, Rotterdam, The Netherlands; [2]Albert Schweizer Hospital, Dordrecht, The Netherlands; [3]Amphia Hospital, Breda, The Netherlands; [4]St Franciscus Hospital, Rotterdam, The Netherlands; [5]Het Van Weel-Bethesda Hospital Dirksland, The Netherlands; [6]Ysselland Hospital, Capelle aan de IJssel, The Netherlands; [7]Reinier de Graaf Hospital, Delft, The Netherlands; [8] Erasmus Medical Center-Sophia Children's Hospital Rotterdam, The Netherlands

P-181
HOW VALUABLE IS „10-TIME ULN THRESHOLD" FOR ATROPHY DETECTION IN SCREENING -DETECTED PATIENTS?
Trovato CM, Montuori M, Nenna R, Valitutti F, De Luca P, Tiberti C, Iorfida D, Lucantoni F, Petrarca L, Mennini M, Anania C, Bonamico M, Cucchiara S
Sapienza University of Rome, Italy

P-182
PANDORA'S BOX: COELIAC DISEASE AMONG FIRST-DEGREE RELATIVES OF SCREENING-DETECTED CELIAC PATIENTS
Mennini M, Montuori M, Trovato CM, Valitutti F, Tiberti C, Lucantoni F, Nenna R, Petrarca L, Bonamico M, Cucchiara S
Sapienza University of Rome, Italy

P-183
CELIAC DISEASE MANAGEMENT: A COMPARISON BETWEEN A CELIAC CENTER AND THE COMMUNITY SETTING
Krawitz S[1], Wrobel P[1], Voorhees K[2], Barbieri J[1], Dimarino A[1], Moleski S[1]
[1]Thomas Jefferson University Hospital, Philadelphia, USA; [2]National Foundation for Celiac Awareness, Ambler, USA

P-184
A COMBINATION OF MSH5 VARIANT ON 6P21. WITH HLA HAPLOTYPES IMPROVES COELIAC DISEASE RISK PREDICTION
Cukrowska B[1], Paziewska A[2], Dąbrowska M[3], Goryca K[3], Piątkowska M[3], Kluska A[3], Mikula M[3], Karczmarski J[3], Oralewska B[1], Rybak A[1], Socha J[1], Bałabas A[3], Żeber-Lubecka N[2], Ambrożkiewicz F[2], Ostrowski J[2,3]
[1]The Children's Memorial Health Institute, Warsaw, Poland; [2]Medical Center for Postgraduate Education, Warsaw, Poland; [3]Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland

Treatment

P-185
QUALITY OF LIFE IN CELIAC DISEASE: DO PATIENTS AND DOCTORS AGREE?
Vriezinga S[1], Farih N[1], van der Meulen-de Jong A[2], Putter H[3], Rings E[1,4], Schaart M[1], Schweizer J[1], Wessels M[1], Mearin ML[1]
[1]Leiden University Medical Center, Department of Pediatrics, The Netherlands; [2]Leiden University Medical Center, Department of Gastroenterology and Hepatology , The Netherlands; [3]Leiden University Medical Center, Department of Medical Statistics, The Netherlands; [4]Erasmus Medical Center, Sophia Children's Hospital, Rotterdam, The Netherlands

P-186
PREVALENCE AND SEVERITY OF GASTROINTESTINAL SYMPTOMS IN LONG-TERM TREATED CELIAC DISEASE PATIENTS
Laurikka P[1], Collin P[2,1], Salmi T[3], Huhtala H[4], Mäki M[5], Kaukinen K[6,1], Kurppa K[5]
[1]School of Medicine, Univeristy of Tampere, Finland; [2]Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Finland; [3]Department of Dermatology, Tampere University Hospital, Finland; [4]Tampere School of Health Sciences, University of Tampere, Finland; [5]Tampere Centre for Child Health Research, University of Tampere and Tampere University Hospital, Finland; [6]Department of Internal Medicine, Tampere University Hospital, Finland

P-187
CHARACTERISTIC AND DIETARY RESPONSE IN CELIAC DISEASE PATIENTS PRESENTING WITH OR WITHOUT ANEMIA
Saukkonen J[1], Kaukinen K[1], Mäki M[1], Koivisto AM[1], Sievänen H[2], Collin P[1], Kurppa K[1]
[1]University of Tampere and Tampere University Hospital, Finland; [2]UKK Institute, Tampere, Finland

P-188
SHORT- AND LONG-TERM OUTCOME OF INCOMPLETE MUCOSAL RECOVERY IN CELIAC DISEASE
Pekki H[1], Kurppa K[1], Mäki M[1], Huhtala H[2], Sievänen H[3], Laurila K[1], Collin P[1], Kaukinen K[1]
[1]University of Tampere and Tampere University Hospital, Finland; [2]School of Health Sciences, University of Tampere, Finland; [3]UKK Institute, Tampere, Finland

P-189
CONTAMINATION OF PROBIOTICS WITH GLUTEN, DETECTED BY LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY
Nazareth S[1], Lebwohl B[1], Voyksner J[2], Green P[1]
[1]Columbia University, New York, USA; [2]ImmunogenX, Pittboro, NC, USA

P-190
DIRECT COSTS IN PATIENTS WITH CŒLIAC DISEASE – A RETROSPECTIVE CLAIMS ANALYSIS
Guandalini S[1], Tundia N[2], Thakkar R[2], Arunajadai S[3], Macaulay D[3], Essenmacher K[4], Fuldeore M[2]
[1]University of Chicago, USA; [2]AbbVie Inc., North Chicago, USA; [3]Analysis Group, Inc., New York, USA; [4]Alvine Pharmaceuticals, San Carlos, USA

P-191
NO BENEFIT OF FOOD-GRADE GLUTENASES IN COELIAC ADOLESCENTS TRANSGRESSING THE GLUTEN-FREE DIET
Korponay-Szabo I[1,2], Tumpek J[2], Gyimesi J[2], Laurila K[3], Papp M[1], Maki M[3], Khosla C[4]
[1]University of Debrecen, Hungary; [2]Heim Pál Children's Hospital, Budapest, Hungary; [3]University of Tampere Medical School, Tampere Center for Child Health Research, Finland; [4]Stanford University, USA

Various

P-192
CATERING GLUTEN-FREE WHEN SIMULTANEOUSLY USING WHEAT FLOUR
Miller K[1], McGough N[2], Urwin H[3]
[1]Food Policy Lead, Coeliac UK ; [2]Director of Policy, Research and Campaigns, Coeliac UK; [3]Research Manager, Coeliac UK

Guidelines for Presenters (Oral and Poster)

Instructions for Speakers

How to Submit Presentations at the Symposium
Please come to the **Speaker's Ready Room (QUADRANT) at least 1 ½ hour** before the beginning of your session. In case your speech has been scheduled for a morning session please come to the Speakers' Ready Room (QUADRANT) one day before the day of your presentation. The Speakers' Ready Room (QUADRANT) location is marked in the Final Program.

The Speakers' Ready Room is located on the 3rd Floor of the Clarion Congress Hotel Prague in the Hall QUADRANT (see floorplan on page 56).

Opening Hours for the Speakers' Ready Room

Sunday, June 21, 2015	16:00–21:00
Monday, June 22, 2015	07:30–17:30
Tuesday, June 23, 2015	07:00–17:00
Wednesday, June 24, 2015	07:30–11:30

Instructions for Posters

Posters
Please plan to be at your poster, and available to answer questions from delegates, at the time of your assigned Poster Session.

Poster Board Numbers
Each poster receives a unique poster board number. You will find the list of posters including the poster board numbers in the Final Program (page 22–52) and also in the poster area.

Poster Area
Each poster is displayed for the whole duration of the Symposium. No guided tours through the poster area are being organized.

Poster Mounting Times

Set-up	Sunday, June 21, from 16:00 until 20:00
Dismounting	Wednesday, June 24, until 10:30

Posters on Display

Monday, June 22, 2015	09:00–17:30
Tuesday, June 23, 2015	08:30–17:30

Best Poster Prize
The Scientific Committee shall award a prize to the best posters. Three best posters will be announced during the Symposium. Authors of the best posters will receive certificates in PDF format by e-mail.

Mobile application

All participants will have a possibility to download mobile application of the ICDS 2015 Symposium. The ICDS 2015 mobile application will enable participants to ask questions to the speakers also during the session.

You can download the mobile application here (search the ICDS 2015):

ANDROID APP ON Google play

iTunes

Windows Phone Store

Coffee with speakers

Lectures and discussions will be combined with short interactive meeting following all sessions, where you can share your experience with other participants, discuss new collaboration and create professional relationship. After every session all speakers presented will be invited to take a coffee in the designated area "Coffee with speakers" (please see the location at the Venue & Floor Plan at page 56) for at least 15 minutes. This would provide an ideal environment to share ideas and personal experiences.

Registration

The Registration Desk is located on the 3rd Floor of the Clarion Congress Hotel Prague.

Opening hours

Sunday, June 21, 2015	15:00–21:00
Monday, June 22, 2015	07:30–17:30
Tuesday, June 23, 2015	07:00–17:00
Wednesday, June 24, 2015	07:30–11:30

Certificate of Attendance

Certificates of attendance will be handed out to participants at the Registration Desk.

General Information

Official Language

The official language for the Symposium is English. Interpreting is provided only for the Patient´s Forum.

Insurance

The organisers do not accept responsibility for individual medical, travel or personal insurance. All participants are strongly advised to take out their own personal insurance before travelling to the Symposium.

Time Zone

The Czech Republic is on Central European Time (CET), which is Greenwich Mean Time (GMT) plus 1 hour. Note that April to October is summer time, i.e. GMT + 2 hours.

Transportation

Each registered participant receives one free public transportation pass at the Registration Desk when registering. This ticket is valid within the dates of the Symposium.

Parking

Free parking spaces in or at the Clarion Congress Hotel Prague are not provided to participants. Expenses for these and other parking space shall be covered by the participants on their own.

Important Telephone Numbers

112: General Emergency for Europe
150: Fire
155: Ambulance
156: Prague Municipal Police
158: Police

Free Wi-Fi

Free Wi-Fi is provided in all the Symposium areas and exhibition.

Wi Fi **SSID: ICDS215**
Password: no password needed

Taxi service

In the city centre, taxis are easy to take from the street but we strongly recommend you use hotel taxis or to call a taxi by phone through the radio taxi service.

We recommend you use following taxi companies:
AAA Taxi: +420 14 0 14
Profi Taxi: +420 14 0 15

Venue & Floor Plan



List of Exhibitors

Company	Stand No.
AbbVie s.r.o.	9
Agrofert a.s.	6
Biomedal S.L.	8
Dr.Schär AG/SPA	1
EUROSPITAL S.P.A.	2
Fria Bröd AB	5
Hermann Kröner GmbH	4
ICDS 2017	7
Labsystems Diagnostics Oy	10
R-Biopharm AG	3
TestLine Clinical Diagnostics s.r.o.	11

Accompanying Events

Welcome Reception

Date: Sunday, June 21, 2015
Time: 17:30–21:30
Admission: Free for all registered participants but requires a confirmation during the registration process.
Venue: Clarion Congress Hotel Prague, Freyova 33, Prague 9

Program of the Welcome Reception

17:30–18:00 Welcome drink and canapés served in the foyer
18:00–18:05 Welcome Video
18:05–18:15 Introductions
18:15–18:30 Musical Performance
18:30–21:30 Dr. Schär Satellite Symposium
(registration required – you can see the detailed program above and register yourself on www.drschaer-institute.com/en/congress/)

The Opening Reception will be held in the Meridian Hall of the Clarion Congress Hotel Prague. Welcome drink and canapés will be served in the foyer prior to the Welcome Reception. The Welcome Reception will be followed by Dr. Schär Satellite Symposium.

Evening River Cruise with dinner, music and sightseeing tour

Date: Tuesday, June 23, 2015
Time: 18:50–21:50
Admission*: 56 EUR
Pick-up: at 17:30 at the Reception Desk of the Clarion Congress Hotel Prague, Freyova 33, Prague 9

**Admission with a valid ticket only. The tickets can be bought at the Registration Desk on-site. Please note that the capacity of the boat is limited.*

Price includes buffet-style dinner, welcome drink and live music

You don't have any plan for tonight yet? We would be pleased to take you by bus to our restaurant tour boat. During three-hour-cruise you can enjoy tasty dinner and live music. Our guide will be available the whole time to provide information about the beautifully illuminated monuments on both banks of the Vltava River as you pass them by. Of course, there is a bar with a wide assortment of alcoholic and nonalcoholic beverages and pleasant serving staff for you on call. The tour includes a short drive through Prague by an air-conditioned bus to show you the most beautiful places of the Old Town, the Jewish Quarter and the New Town. After the cruise you will be brought back to your hotel.

Map with recommended gluten-free restaurants in Prague



Celimmune is launching two Phase 2 trials within the next 12 months to test AMG 714 for diet non-responsive celiac disease and Type II refractory celiac disease (small bowel T cell lymphoma)

Please join us on June 24 at 11:00 for Dr. Francisco Leon's presentation "Rationale for AMG 714, an Anti-IL-15 mAb, in the Treatment of Celiac and Refractory Celiac Disease" in the Scientific Forum of ICDS

celimmune

To learn more about us, visit www.celimmune.com

Targeting
Transglutaminase
for research and medicine!

- Transglutaminases
- Assays and Substrates
- Inhibitors
- Antibodies
- ELISAs and Antigens

zedira®

We provide the toolbox for your essential work!

Zedira GmbH
Roesslerstrasse 83
64293 Darmstadt
Germany

Phone: +49 61 51 / 32 51 00
Fax: +49 61 51 / 32 51 19
E-mail: contact@zedira.com
Web: www.zedira.com

Meet Zedira's managing partner Martin Hils at ICDS 2015!
Send an e-mail to contact@zedira.com

Contact us for receiving your personal catalogue hardcopy containing more than 200 TGase specialty reagents!

iVYDAL In Vitro Diagnostics



Immunodetection of gluten peptides in fecal samples to monitor gluten free diet (GFD) adherence.[1,2]

Why should GFD adherence be monitored?

- It is difficult to avoid gluten exposure because it is one of the most frequent food ingredients.
- Full adherence to GFD reduces long-term risk of complications such as nutritional deficiencies, low bone mineral density and lymphoma.[3]
- More than 45% of patients still exhibit intestinal damage even after a year following a GFD.[4,5]
- Demonstration of strict GFD is needed in order to diagnosed Type II Refractory Celiac Disease, an in situ small bowel T cell lymphoma.

Why measuring gluten in stools?

Current non-invasive methods to assess compliance with the GFD (dietary questionnaires, serological tests, permeability and fecal calprotectin tests) are neither sensitive nor specific. Biopsy and histology are invasive and not practical to monitor exposure to GFD.

iVYLISA GIP directly detects Gluten Immunogenic Peptides (GIP) in stool samples.

Presence of GIP in human samples correlates with histology.

Most of celiac patients with no detectable GIP did not show any histological damage in the intestinal mucosa

Villous atrophy was observed in all celiac patients with high levels of GIP

Product Indications

- Assessment of compliance with GFD in celiac disease and gluten intolerance.
- Assessment of gluten contamination in recently diagnosed patients or in patients who show signs or symptoms suspicious of gluten exposure.
- Verification of gluten consumption prior to the diagnosis of celiac disease (avoid false negatives in cases when patients stop eating gluten before the formal diagnosis).

For further information consult our website
biomedal.com

Developed by: Biomedal

References:

1. Auricchio. 2012. An innovative approach to measure compliance to a gluten-free diet. Am. J. Clin. Nutr. 95:537-538.
2. Comino et al. 2012. Monitoring of gluten-free diet compliance in celiac patients by assessment of gliadin 33-mer equivalent epitopes in feces. Am. J. Clin. Nutr. 95:670-677.
3. Lebwohl et al. 2013 Mucosal Healing and Risk for Lymphoproliferative Malignancy in Celiac Disease. An. Int. Med. 159:169-176.
4. Press Release. Alvine Pharmaceuticals Presents Celiac Disease Sumptom Frequency and Severity Study Results at the 2012 American College of Gastroenterology Meeting. http://www.alvinepharma.com/press-oct2412/ (Web visited 05/11/2013).
5. Hall et al. 2013. Intentional and inadvertent non-adherence in adult coeliac disease. A cross-sectional survey. Appetite 68: 56-62.

Vše o celiakii na jednom místě

BEZ LEPKU www.bezlepek.cz

- Komplexní informace o onemocnění
- Novinky a trendy v léčbě
- Rady a tipy pro život s celiakií
- Bezlepkové recepty pro každý den
- Tipy na bezlepkové restaurace
- Zajímavosti a rozhovory

+ Velký katalog bezlepkových produktů na českém trhu

www.bezlepek.cz
www.facebook.com/bezlepek

Penam · Vodňanské kuře · Krahulík · Tatra · Knorr · Olma

We thank our sponsors for the support of the 16th International Coeliac Disease Symposium (ICDS 2015)

Gold Sponsor

Innovating special nutrition Dr Schär

Silver Sponsor

AGROFERT

Bronze Sponsor

MADETA
Tak chutná mléko

Sponsors

abbvie

fria GLUTEN FREE
You can't tell the difference

KRÖNER STÄRKE
... the power of nature!

LABSYSTEMS DIAGNOSTICS
speaking your language

r-biopharm

Notepads & Pens Sponsor

Innovating special nutrition Dr Schär

Badge Laynards Sponsor

celimmune

ICDS 2015

www.icds2015prague.com